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Preface
Postoperative pain is prevalent and not optimally managed in most patients.  Pain can 
lead to adverse emotional and systemic consequences.
Numerous device orientated studies have been done in other countries looking at the 
effect of infusions of local anaesthetic at the wound site postoperatively via an 
elastomeric pump.  There have however been no similar studies done in South Africa.  
The aims of this study was to assess whether the use of an incisional wound catheter 
and 0.39% bupivacaine infusion in patients post total abdominal hysterectomy for a 
30 hour period will decrease opioid requirements compared to a control group having 
only systemic analgesia.  Pain intensities were also documented at set observation 
periods.
The opioid requirements between the 2 groups were comparable however the 
participants who had the bupivacaine infusion in their incisional site had less pain 
intensity scores until 6 hours post operation and had less pain intensity on movement 
at 30 hours post operation. 
A bupivacaine infusion in the incisional site decreases pain intensity in the above 
mentioned parameters but does not reduce opioid requirements.
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11 Chapter One: Overview of the study 
1.1 Introduction
In this chapter an overview of the study is provided.  This includes the background to the 
study, the problem statement, the purpose, hypothesis, objectives, the importance of the 
study, relevant definitions, overview of methodology, validity and reliability and ethical 
considerations.  The chapter concludes with a brief outline of the clinical study.
1.2 Background to the study
Pain is rated as a highly undesirable postoperative outcome (1).  Post operative pain is 
often negligently overlooked and remains under-treated (1, 2). Postoperative pain, 
especially when poorly controlled, results in acute adverse physiologic responses and 
chronic effects (1). Inadequately controlled pain may extend the length of hospital stay and 
predispose to expensive, time-consuming complications.  Control of acute postoperative 
pain, timing, duration, and fashion with which it is implemented, may be important in 
facilitating short and long-term patient convalescence after surgery (1). 
The two modalities of pain relief are systemic (opioid and non-opioid) analgesia and 
regional analgesia (neuraxial and peripheral techniques).  Opioid analgesics are one of the 
cornerstone options for the treatment of postoperative pain (1). Intravenous patient 
controlled analgesia (PCA) optimises delivery of analgesic opioids and minimizes the 
effects of pharmacokinetic and pharmacodynamic variability among individual patients (1).  
2Compared with traditional ‘as required’ analgesic regimens, intravenous PCA provides 
superior postoperative analgesia, improves patient satisfaction and may decrease the risk of 
pulmonary complications (1).  It also ensures that the patient controls the amount and 
therefore is independent on the nursing care to provide the necessary analgesia. 
Another mode of pain relief is regional peripheral techniques.  These techniques use local 
anaesthetics and additives to provide analgesia.  Intrathecal and continuous epidural 
analgesia provide excellent postoperative analgesia but require extended patient  
monitoring (3).
Peripheral techniques may have several advantages over systemic opioids. Notably,
superior analgesia, decrease in opioid-related adverse effects and avoidance of neuraxial 
complications (1).
Local analgesia is a well recognised component in multimodal analgesia. It is inexpensive, 
relatively safe and simple to use.  Infusions of local anaesthetic through catheters are a new 
and evolving area of postoperative pain management (4, 5).
The measurement of pain is difficult as pain is a subjective experience with multimodal 
components making an objective measurement for a patient’s pain difficult.  There are 
numerous pain measurement tools. Self-reported unidimensional instruments include the 
visual analogue scale (VAS).  This scale is a relatively simple and efficient instrument to 
administer (6). 
In the international arena of postoperative pain control many protocols for pain control are 
used following total abdominal hysterectomy.  The Procedure Specific Postoperative Pain 
Management (PROSPECT) website contains recommendations for several postoperative 
pain protocols for patients undergoing total abdominal hysterectomy (7).  
3This committee recommends from evidence from randomised control trials that 
postoperatively patients post total abdominal hysterectomy (TAH) should have “strong” 
opioids by intravenous PCA or fixed intravenous dosing, titrated to pain intensity.  
Continuous wound infiltration of local anaesthetic after closure is not recommended as 
currently there is limited procedure-specific evidence (8).
The standard drug against which other opioids are compared is morphine (9).  Morphine is 
classed as a “strong” opioid. Morphine is a very efficient analgesic but has a number of 
adverse side effects. The large quantities of morphine required, can lead to pruritis, fatigue, 
gastrointestinal adverse effects (nausea, vomiting and ileus), urinary retention, and reduced 
ability to mobilize due to drowsiness (10, 11, 12).  Respiratory depression is a potentially 
dangerous adverse effect (11). 
Multimodal analgesia helps reduce opioid consumption and thus minimises opioid side 
effects (3, 9).  This paradigm of multimodal analgesia has developed to attempt to reduce 
side effects of analgesic medication and provide satisfactory pain relief.   Internationally 
this has led to research into which combination protocols are the most effective in relieving 
post operative pain.
In the South African context various pain relief protocols are implemented.  In the setting 
of Rahima Moosa Mother and Child hospital two pain protocol options can be 
implemented.  Firstly, patients can be prescribed 10 mg Omnopon-FreseniusR (this is a 
combination of morphine hydrochloride, codeine hydrochloride and papaverine 
hydrochloride) eight hourly with paracetamol and ibuprofen tablets when patients can take 
fluids orally (usually 24 hours post operation).  The other option, introduced in 2008, is an 
intravenous morphine PCA.  The program for the morphine is intravenous 1mg morphine 
4bolus with a lockout time of 6 minutes. This service is run by the Department of 
Anaesthesiology and Pain Department of the Helen Joseph/Rahima Moosa Mother and 
Child Hospital Complex.  
The pain relief of a local anaesthetic continuous infusion in the incisional site has not been 
used in a public hospital.  Factors involved are the cost implications of the required 
equipment, as well as the lack of evidence of its efficiency in reducing patients’ pain.
This technique of acute pain management, has not been studied in a healthcare setting of a 
developing country such as South Africa, as seen by a PubMed MESH search in October 
2008  of the following terms: ”South Africa”, “local anaesthetic infusions” and 
“postoperative pain management in South Africa”.  There were no research articles 
concerning the above terms in the two non-accredited appropriate journals, namely the 
South African Medical Journal and the South African Journal of Anaesthesia and 
Analgesia.  
In our setting (a South African public hospital), we do not have the resources (nursing 
skills and financial means) to maintain an epidural service in the post operative surgical 
wards. It has been noted that our acute pain management in patients post operation is not 
optimal (13).  Local anaesthetic infusions in the incisional site may improve the acute 
postoperative pain in these patients and be logistically possible as they are easier to manage 
and care for in the ward.  Thereby increasing both patient and nurse satisfaction.
51.3 Problem Statement
At Rahima Moosa Mother and Child hospital it has been observed that pain is prevalent 
and poorly managed postoperatively in patients following total abdominable hysterectomy.  
A more effective pain management protocol needs to be introduced.  Morphine patient 
controlled analgesia is an effective pain relief option, however there are concomitant opioid 
side effects.  The question arises whether a new technique of bupivacaine infusion into the 
incisional site reduces pain and consequently decreases patients’ opioid requirements and 
therefore opioid side effects.  
1.4 Hypothesis
There is no decreased opioid consumption and/or decreased pain intensity in patients with 
bupivacaine infusions into the incisional site compared to the control group.
1.5 Aim 
The aim of the study is to determine whether there is a reduction in patients’ opioid 
requirements post total abdominable hysterectomy and a decrease in the patients’ pain 
intensity with the use of a bupivacaine infusion into the incisional site.
61.6 Objectives
The aims of the study will be justified by the following objectives.
1.6.1 Primary Objectives
 To determine patients’ opioid consumption post total abdominal hysterectomy  in the 
presence of a bupivacaine infusion in the incisional site
 To determine opioid consumption in patients’ post total abdominal hysterectomy 
without the presence of a bupivacaine infusion in the incisional site 
 Compare the use of opioid consumption in the two above-mentioned groups of 
patients post total abdominal hysterectomy 
1.6.2  Secondary Objectives:
 To determine patients’ post operative pain dynamic visual analogue scale (VAS) 
scores in patients post total abdominal hysterectomy  in the presence of a bupivacaine 
infusion in the incisional site at set time points
 To determine patients’ post operative pain dynamic VAS scores in patients post total 
abdominal hysterectomy without the presence of a bupivacaine infusion in the 
incisional site at set time points 
 To compare the dynamic VAS scores between the two above mentioned groups
 To determine patients’ post operative pain static VAS scores in patients post total 
abdominal hysterectomy  in the presence of a bupivacaine infusion in the incisional 
site at set time points
 To determine patients’ postoperative static VAS scores in patients post total 
abdominal hysterectomy without the presence of a bupivacaine infusion in the 
incisional site at set time points
 To compare the static VAS scores in the two above mentioned groups
7 To determine the incidence of opioid adverse effects in patients post total abdominal 
hysterectomy  in the presence of a bupivacaine infusion in the incisional site at set 
time points
 To determine the incidence of opioid adverse effects in patients post total abdominal 
hysterectomy without the presence of a bupivacaine infusion in the incisional site at 
set time points 
 To compare the incidence of opioid adverse effects in the two above mentioned 
groups
1.7 Location of the study
The study took place at the Rahima Moosa Mother and Child Hospital (formerly 
Coronation Hospital), Gauteng Province, South Africa. 
Rahima Moosa Mother and Child Hospital is a woman and child hospital associated with 
the University of the Witwatersrand.  It is a secondary regional hospital acting as a referral 
hospital for smaller hospital clinics.
1.8 Research assumptions and definitions
Throughout this research report the following assumptions with their definitions will be 
made as outlined in the table below:
8Table 1.1: Research assumptions and definitions
Assumption Definition
Bupivacaine A local anaesthetic agent that produces reversible 
blockade of neural transmission (9). 
Total abdominal hysterectomy The whole uterus including the cervix is removed, with 
as little vagina as possible.  The ovaries and tubes may 
or may not be removed depending on the indication 
(14).
Visual analogue scale A graphic rating scale using the combination of rating 
on a line and by checking descriptive terms (15).
Dynamic pain intensity The pain rating that the patient experiences on 
movement, deep breathing or coughing.
Static pain intensity The pain rating that the patient experiences in bed at 
rest.
1.9 Ethical considerations
1.9.1 Authorisation
An approval to conduct the study was obtained from the Ethics Committee of the 
University of the Witwatersrand, clearance number M070701 (Appendix A).
 Approval by the Postgraduate Committee of the University of Witwatersrand was granted.
Approval for the study was obtained by the hospital superintendent at the time and the 
Head Matron of Rahima Moosa Mother and Child Hospital (Appendix B).
91.9.2 Patient Consent
Patients who met the selection criteria for this study were given a verbal explanation of the 
study and follow-up requirements by the clinical investigator.  Each patient was supplied 
with a copy of the Patient Information Form (Appendix D) and the Consent Form 
(Appendix E) which they read in their own time.  If the patient was then willing to 
participate in this study they signed the informed consent document.
1.9.3 Confidentiality of Subject Records
Confidentiality of subject data was maintained at all times.  Subject anonymity was 
guaranteed.  All documentation relating to the subject was kept in a secure location.  
Subjects were made aware that clinical data was stored electronically.
Confidentiality will be guaranteed in any resulting publication. Subjects were made aware 
that data collected as part of this study may be published but anonymity was guaranteed.  
1.9.4 Declaration of Helsinki
The World Medical Association Declaration of Helsinki and its subsequent amendments
formed the accepted basis for the ethical conduct of this study (16).
1.10 Regulatory Requirements
Regulatory Approval was not required for this particular study as the infusion device and 
bupivacaine are commercially available.
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1.11 Research methodology
1.11.1 Research design
This was a contextual, prospective, parallel, single blinded, randomised control trial. 
1.11.2 Study population
The study population for this study were women undergoing total abdominal hysterectomy 
at the Rahima Moosa Mother and Child Hospital, Johannesburg.
1.11.3 Study Sample
1.11.3.1 Sample Statement
A biostatistician calculated that a sample size of at least 18 subjects per group will have 
power in excess of 90 % to detect a decrease of at least 20 milligrams over a time period of 
48 hours in morphine use using a one-sided t-test.  The standard deviation assumed was 20 
units which is the range of expected morphine use (10 – 130mg) divided by 6. The latter 
assumes a symmetrical distribution, which is unlikely.
1.11.3.2 Sampling method 
The study sample included all patients undergoing total abdominal hysterectomy during 
daytime hours.  The patients all had a routine general anaesthetic and standard analgesia 
intraoperatively.  Only patients who consented to take part in the study were included in the 
sample study.  
A consecutive convenience sampling method was used in this study.  The most readily 
accessible gynaecological patients who presented for surgery were included.  It is noted 
that a convenience sample cannot fully represent the study population.  However, 
11
consecutive sampling is the most reliable for convenience sampling as research bias is 
limited (17).  
Selection bias was avoided by having the control device inserted in alternate participants.
1.11.4 Selection criteria
1.11.4.1 Inclusion criteria 
The following inclusion criteria were used for the study:
 ASA I-II patients
 Pfannenstiel incision only.
 Informed consent to participate in this clinical study
1.11.4.2 Exclusion criteria 
The following exclusion criteria were used for the study:
 Contraindication to general  anaesthesia
 Allergy to any of the study medications
 History of alcohol/drug abuse 
 Major medical disease such as cardiovascular, pulmonary, metabolic, renal, 
neurological or psychiatric disease
 Patients with clinically significant bacterial infection
1.12 Methodology
Patients scheduled for a total abdominal hysterectomy were assessed by the investigator 
pre-operatively. If the inclusion criteria were met, an informed consent to participate in the 
trial was obtained. 
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Patients who consented to participate in this clinical study were randomly assigned to either 
receiving a bupivacaine infusion into their incisional site and a morphine patient controlled 
analgesia (PCA) pump, or to receive a morphine PCA pump only.
The opioid requirements as well as number of attempts for opioid administration were 
documented at set intervals together with patients’ visual analogue scale (VAS) for pain 
intensities.
1.12.1 Data Analysis
Data analysis was done in consultation with the biostatistician.  Descriptive statistics mean, 
standard deviation, median, range and 95% confidence intervals was employed to 
summarise the observed data that was opioid consumption and VAS scores at set time 
periods.  Groups were compared using the two-sample t-test.  Also a Mann-Whitney U-test 
was employed for the skewed data   Testing was at the 0.05 level of significance.  A 
statistician, assisted in the format and layout of the graphs and figures. 
1.13 Significance of the study
The results of this study will be of primary interest to patients following total abdominal 
hysterectomy and to hospitals providing postoperative pain management.  This study will 
prove to be valuable in determining whether local anaesthetic infusions in the surgical site 
will decrease opioid requirements and improve patient satisfaction.  This could aid hospital 
management in determining whether this pain relief device is worth obtaining for patient 
care.
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 This study shall also be of interest to the South African Chapter of the International 
Association of the Study of Pain (IASP).  This study shall also be of interest to the South 
African Society of Anaesthesiologists (SASA), and the South African Journal of Regional 
Anaesthesia, which as a body proposes protocols/guidelines for the safe practice of 
anaesthesia and pain management. 
1.14 Validity 
The visual analogue scale is a well documented tool in measuring pain as a single quality 
that only varied in intensity.  The average group scores can be treated as ratio data and 
there is good evidence for validity (6).
The morphine PCA pumps were all programmed identically for the study patients.  The 
pumps program was locked and was not adjusted while the participant was in the trial.
The anaesthetic and surgical technique was a standardised procedure.  The validity was 
confirmed by the researchers who checked the surgical notes and anaesthetic charts 
postoperatively.
1.15 Reliability
The data was collected consistently within the given time periods by two researchers to 
ensure reliability.  
Quality control was achieved with the use of new morphine PCA pumps of the same make, 
the CADD-Legacy PCA Pump Model 6300 (Smith Medical).  The PCA pumps were only 
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used on the clinical study participants during the clinical study.  They had all been 
calibrated and serviced appropriately for the clinical study to ensure reliability. 
The amounts in milligrams of morphine given and the patients attempted boluses (that been 
the number of times the participant pressed the button for a morphine bolus for 
breakthrough pain but was not delivered as the lockout time was not exceeded) were 
recorded from the PCA computer which automatically records the number of attempts and 
amount of doses that the pump gave to the patient.
The participants were operated on by different teams of surgeons and anaesthesiologists.  
The surgeons reliably preformed the total abdominal hysterectomy with a uniform surgical 
technique.  The group of anaesthesiologists who provided the general anaesthetic for the 
study participants gave a uniform general anaesthesia with only opioid analgesia.  This was 
ensured with regular interactions with the researches and presentations at departmental 
meetings.  This ensured reliability in surgical and anaesthetic techniques of the study 
participants. 
1.16 Potential limitations
The following limitations of this study have been identified:
The study population may not be representative of the national group of women undergoing 
total abdominal hysterectomy but addresses a clinical setting relevant locally.
The pain evaluations during the postoperative days were not performed under blinded 
conditions because of the clinical setting of this study.  Rigorous scientific methods require 
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placing a subfascial catheter to all patients. Evident ethical reasons restrain our application 
of this method. Bias may occur due to the design of the trial, not being double-blinded.  
These limitations will be acknowledged as part of the discussion of the study’s results.
1.17 Overview of the study
This study will be presented as follows:
Chapter 1: Overview of the study
Chapter one will provide an introduction for the study and will include the background to 
the study, the problem statements, aim and objectives.  This chapter will also include the 
research assumptions, demarcation of the study and its purpose.  It will contain a brief 
explanation of the research methodology and limitations.
Chapter 2: Literature review
This chapter will be a review of the literature relevant to this clinical study. 
Chapter 3: Research methodology
Chapter three will contain the research methodology used, including the research design, 
the study setting, randomisation of trial participants, data collection procedures, validity 
and reliability of the study  and ethical considerations. 
Chapter 4: Data analysis and discussion of results
In this chapter the results, including the visual analogue scale scores, opioid consumption 
and the incidence of opioid adverse effects, of the two groups will be analysed. In addition 
this chapter will contain the descriptive statistics analysis and the analysis for statistical 
differences between the two clinical study groups.
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Chapter 5: Summary, conclusions, limitations and recommendations.
In this chapter a summary and the conclusions from the main findings are presented, 
followed by a discussion of the limitations of the study and recommendations for clinical 
practise and for further research in this area.
1.18 Summary
Postoperative pain is prevalent and not optimally managed in most patients.  Pain can lead 
to adverse emotional and systemic consequences.
Numerous device orientated studies have been done in other countries looking at the effect 
of infusions of local anaesthetic at the wound site postoperatively via an elastomeric pump.  
There have however been no similar studies done in South Africa.  Knowledge of whether 
these pain relief devices are effective in patients following total abdominal hysterectomy in 
Rahima Moosa Mother and Child hospital could increase our choice of pain relief options 
in these patients.
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2 Chapter Two:  Literature Review
2.1 Introduction
In this chapter a review of the relevant literature is presented.  The review begins with a 
discussion on postoperative pain and its associated problems.  This will be followed by a 
review of pain relief options.  The tools for monitoring and measuring pain will be 
discussed. Pain relief options for patients post total abdominal hysterectomy will be 
reviewed both in the international setting as well as the setting at Rahima Moosa Mother 
and Child hospital.
2.2 Postoperative Pain
2.2.1 Prevalence
Pain is rated as a highly undesirable postoperative outcome (1). Post operative pain is often 
negligently overlooked and remains under-treated (1, 3).  In an audit at a public hospital a
large proportion (37%) of patients will suffer severe pain 24 hours after surgery.  After 24 
hours, 43% of the patients had a pain score higher than 4 (out of 10) on movement (13). 
The same audit showed that only 14% of patients received their pain medication as 
prescribed at 24 hours. This trend continued at 48 and 72 hours, with respectively 18% and 
21% of prescriptions being followed (13).  
There is great variability in the rate of resolution of surgical pain (1). In one study 26% of 
surgical patients reported experiencing severe pain after 72 hours (13).
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2.2.2 Complications of postoperative pain
Postoperative pain, especially when poorly controlled, results in acute adverse physiologic 
responses and chronic effects (1). Uncontrolled postoperative pain activates the 
sympathetic nervous system, which may contribute to morbidity or mortality.  Activation 
of the sympathetic nervous system causes an increase in myocardial oxygen consumption, 
which may be significant in the development of myocardial ischemia and infarction.  
Sympathetic activation may also delay return of postoperative gastrointestinal motility and 
may develop into paralytic ileus (1).  Unrelieved pain increases the stress response and 
aggravates wound healing (18).  Beneficial effects of analgesia on functional rehabilitation 
and the duration of convalescence have been suggested repeatedly (19).   Preclinical studies 
show that neuronal expression of new genes – the basis for neuronal sensitisation and 
remodelling, occurs within 20 minutes of injury resulting in increased sensitisation to 
chronic pain syndromes (20).  Even brief intervals of acute pain can induce long-term 
neuronal remodelling and sensitisation (“plasticity”), chronic pain and lasting 
psychological distress (20, 21).  This nociceptive process is not a hard-wired characteristic 
but is a plastic and dynamic process. Clinical studies also suggest that intensity and 
duration of acute postoperative pain are significant predictors of chronic pain development.   
In commonly used animal models for neuropathic pain, both spontaneous activity and pain 
behaviours appear within the first 12 hours to 2 days post-injury (22). Inadequately 
controlled pain may extend the length of hospital stay and predispose to expensive, time-
consuming complications. Recognition of economical and humanitarian benefits of pain 
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control has prompted worldwide attention from professional group insurers, and 
governments (20).
2.3 Pain management
Control of acute postoperative pain, timing, duration, and fashion with which it is 
implemented, may be important in facilitating short and long-term patient convalescence 
after surgery (1). 
There is no consensus on the best method for controlling pain (18).  
Many options are available for the treatment of postoperative pain.  Broadly there are two 
main options: 
 Systemic (opioid and non-opioid) analgesia 
 Regional analgesia (neuraxial and peripheral techniques).  
2.3.1 Systemic analgesia
One of the main groups of systemic analgesia is the opioids. The standard drug against 
which other opioids are compared is morphine (9).  Morphine is classed as a “strong” 
opioid.  Morphine is a very efficient analgesic but has a number of adverse side effects. 
These are pruritis, fatigue, gastrointestinal adverse effects (nausea, vomiting and ileus), 
urinary retention, and reduced ability to mobilize due to drowsiness (10, 11, 12).  
Respiratory depression is a potentially dangerous adverse effect (11). 
Intravenous patient controlled analgesia (PCA) optimises delivery of analgesic opioids and 
minimizes the effects of pharmacokinetic and pharmacodynamic variability among 
individual patients (1).  Compared with traditional ‘as required’ analgesic regimens, 
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intravenous PCA provides superior postoperative analgesia, improves patient satisfaction 
and may decrease the risk of pulmonary complications (1).  It also ensures that the patient 
controls the amount and therefore is independent on the nursing care to provide the 
necessary analgesia.
Multimodal analgesia helps reduce opioid consumption and thus minimises opioid side 
effects (3, 23, 24).  This paradigm of multimodal analgesia has developed to attempt to 
reduce side effects of analgesic medication and provide satisfactory pain relief.   Principles 
of multimodal strategy require multidisciplinary collaboration and change in the traditional 
principles of postoperative care. Additional resources and expansion of the traditional acute 
pain service might be difficult in the current economic climate (1).
2.3.2 Non-systemic analgesia
Regional and peripheral techniques can provide superior analgesia, particularly when local 
anaesthetics are used, compared with systemic opioids. The use of these techniques may 
even reduce morbidity and mortality (1, 25, 26).  Intrathecal and continuous epidural 
analgesia provide excellent postoperative analgesia but require extended patient monitoring 
(27, 28).  
Epidural analgesia is associated with: hypotensive episodes (incidence up to 7%), motor 
block (2-3%), nausea and vomiting (20-30%) and urinary retention (18 – 80%).  The 
dangerous complication of a spinal haematoma has an incidence of 1 in 3100 for 
postoperative epidural analgesia in certain groups of patients (1).
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Peripheral techniques may have several advantages over systemic opioids notably, superior 
analgesia and a decrease in opioid-related adverse effects.  Peripheral techniques also avoid 
neuraxial complications (1).
2.3.3 Local anaesthesia
Local anaesthesia is a well recognised component in multimodal analgesia. Local 
anaesthetics have an opioid sparing effect thereby decreasing opioid adverse effects (18).  
Local anaesthetics have multiple molecular and cellular actions (29).  
Local anaesthetics block sensory inflow and can completely stop nociceptive transmission. 
It is also possible that repeated local anaesthetic wound instillation could 
decrease/modulate injury induced C-fibre activity with consequent attenuation of peripheral 
and central sensitisation and possibly decrease the incidence of hyperalgesia (24, 28).  
Local anaesthetics provide good analgesia.  In addition, they are inexpensive, relatively 
safe and simple to use. They are locally anti-inflammatory (24, 30) and have bacteriostatic 
and antimicrobial effects (30).   
Local anaesthetics can be applied topically, subcutaneously or infiltrated into surgical sites.  
It is simple to inject local anaesthetics into the surgical wound and can be very efficacious 
(1, 12, 31, 32).  They can also be used for single shot blocks for abdominable surgery such 
as the transverses abdominal plane block (33). However a single shot of local anaesthetic in 
the abdominal wall post total abdominal hysterectomy has shown no opioid-sparing effect 
(34).  They can also be infused into the operative site via a pump (10, 21).  This drug 
delivery system can give prolonged analgesia with few adverse effects, increased patient 
satisfaction and possibly expedite recovery (18).  The technological improvements in the 
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needles and catheter insertion technique with practical drug delivery systems have 
increased the use of this modality for analgesia (18).  
2.3.3.1 Local anaesthetic infusions
Infusions of local anaesthetic through perineural, incisional and intra-articular catheters are 
a new and evolving area of postoperative pain management (35, 36).  The data for optimal 
parameters, that is local anaesthetic concentration, use of adjuvants (for example opioids) 
and continuous versus PCA or intermittent boluses for peripheral analgesia have not been 
determined (1, 11, 28, 37). In one study it was shown that 0.5% bupivacaine infiltrate 
infusion gave better analgesia than a 0.25% bupivacaine solution (12).   The strengths of 
bupivacaine used in clinical studies are from 0.1 - 0.5% (18, 28). 
There are 2 types of infusion pumps: 
1) Elastomeric or spring- activated pumps
2) Battery powered electronic pumps
The elastomeric pump has simple equipment and technology and therefore needs a simple 
explanation concerning the equipment to patients and caregivers.  The balloon pumps 
supply the required force to deliver anaesthetic agents to the surgical site and therefore 
needs no manual compression (18).  Disadvantages are that their have inaccurate infusion 
rates and no ability to adjust/customise the infusion rate or provide boluses. The accuracy 
(infusion at affixed rate) and consistency (the majority of time at a fixed rate) depends on 
the location of catheter system and concentration and amount of local anaesthetic.  The 
infusion rate is regulated by the temperature detection devices which are calibrated to skin.  
Complications regarding the local anaesthetic infusions are local anaesthetic toxicity 
especially if the catheter migrates into the intravascular space (18).  Clinical impact of long 
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term myotoxic effects still have to be assessed especially regarding calcific myonecrosis 
(38).  Controversies regarding local anaesthetics and neurotoxicity, myotoxicity and 
cartilage toxicity are present (38).  The extent of muscle injury seems to be directly related 
to the dose and number of drug administrations.  In the clinical setting local anaesthetic-
induced myotoxicity seems to be rare (28, 37, 39).  This is probably because local 
anaesthetic-induced analgesia and anaesthesia is achieved at a dosage insufficient to 
produce clinically recognisable myotoxicity (37). 
Some clinicians have a preference for incisional catheter techniques because of their 
simplicity and safety over perineural catheters (36).  Liu et al published a meta-analysis of 
trials using continuous infusions through wound catheters for postoperative analgesia.  The 
outcome showed reduced pain scores and/or opioid consumption. Procedures included 
orthopaedic surgery, abdominal surgery, cardiothoracic surgery and gynaecological 
surgery. In general there was a 32% reduction of pain scores at rest and movement, 25% 
decreased need for opioids, 15% decreased risk of post operative nausea and vomiting and 
30% increase in patient satisfaction.  There was also a one day reduction of hospitalisation 
but the data were from limited number of patients (24, 40).  These results were especially 
noted in orthopaedic patients.  No cases of systemic toxicity or wound infection were 
reported (24). The meta-analysis found that randomised controlled trials involving 
gynaecological procedures showed a slight majority (5/9) of improved analgesic efficacy 
especially pertaining to the immediate postoperative period (24).  Positive results were also 
noted in a study in patients who had an infusion of local anaesthetic in their incisional 
wound post median sternotomy (12) and inguinal hernia repair (41). 
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Current evidence from Canada and Sweden suggests that infusions of local anaesthetic 
techniques are effective, feasible and safe in the home environment if appropriate patient 
selection, routines and organization for follow-up are in place (24, 30, 40, 42).  The local 
anaesthetic is infused into the operative site by a pump.  Benefits include quicker recovery, 
decreased complications associated with narcotics and possibly a reduction in treatment 
costs (40).  In the study by Gupta et al regarding gynaecological operations and 
intraperitoneal local anaesthetic infusion, it was noted that in addition to the reduced 
postoperative pain and opioid-sparing effects, there were no signs or symptoms of local 
anaesthetic toxicity and no clinical or laboratory evidence of infection in any of the trial 
groups (10). A similar study was done to evaluate the efficacy and patient satisfaction with 
incisional analgesia with a subfascial catheter compared to epidural analgesia for pain relief 
following caesarean section.  The subfascial catheter provided satisfactory pain relief with 
patient satisfaction similar to that seen with epidural analgesia (43).  This is in contrast to 
the study of postoperative pain in patients post caesarean section comparing systemic 
morphine, Ketorolac and a subcutaneous saline placebo infusion with a levobupivacaine 
subcutaneous infusion. In this study there was significantly less pain shown by the VAS 
scores in the group receiving systemic analgesia (44).
Problems (40 cases) that have been reported from the use of these catheter devices to the 
US Food and Drug Administration have been reported from surgeries and are possibly 
isolated incidents or sentinel events these are tissue necrosis, surgical wound infection and 
cellulitis.  Tissue necrosis could be the result of using adrenaline in the local anaesthetic 
mixture (45).    
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2.4 Pain measurement tools
The measurement of pain is difficult as pain is a subjective experience with multimodal 
components including individual, genetic, cultural and sociological factors.  This makes an 
objective measurement for a patient’s pain difficult.  There are numerous pain 
measurement tools. Self-reported unidimensional instruments include the visual analogue 
scale.  This scale is a relatively simple and efficient instrument to administer especially for 
acute pain (6).  Other measurements for acute pain are the intensity described in words or 
indirectly by opioid consumption, patients’ satisfaction in analgesic protocols and the 
patients’ mobility (46).  
  
2.5 Post operative pain relief for total abdominal hysterectomy
In the international arena of postoperative pain control many protocols for pain control are 
used following total abdominal hysterectomy.  The Procedure Specific Postoperative Pain 
Management (PROSPECT) website contains recommendations for several postoperative 
pain protocols for patients undergoing total abdominal hysterectomy.  The committee 
recommends pain management options after evaluating information from a systematic 
review in addition to transferable evidence and expert knowledge.  These recommendations 
are graded based on the level of evidence from studies in accordance with the Oxford 
Centre for evidence based medicine (7).  
This committee recommends (evidence from randomised control trials), that 
postoperatively patients post total abdominal hysterectomy should have “strong” opioids by 
intravenous PCA or fixed intravenous dosing, titrated to pain intensity.  Cyclo-oxygenase 2 
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(COX- 2) selective inhibitors and conventional non-steroidal anti-inflammatory drugs 
(NSAIDS) should be used in combination with opioids for analgesia.  Paracetamol should 
be used in combination with NSAIDS in moderate to low intensity of pain.  Moderate pain 
is defined as pain with a VAS >30/100 but <50/100.  Low intensity pain is defined as pain 
with a VAS <30/100 (7).
Continuous wound infiltration of local anaesthetic after closure is not recommended as 
currently there is limited procedure-specific evidence. (8)
Literature shows that patients post total abdominable hysterectomy on average require 
70mg of morphine over a 24 hour period (47).  
2.5.1 Current practice for pain relief post total abdominal hysterectomy
In the South African context various pain relief protocols are implemented.  In the setting 
of Rahima Moosa Mother and Child hospital two pain protocol options can be 
implemented.  Firstly, patients can be prescribed 10 mg Omnopon-FreseniusR (this is a 
combination of morphine hydrochloride, codeine hydrochloride and papaverine 
hydrochloride) eight hourly with paracetamol and ibuprofen tablets when patients can take 
fluids orally (usually 24 hours post operation).  The other option, introduced in 2008, is an 
intravenous morphine PCA.  The program for the morphine is IV 1mg morphine bolus with 
a lockout time of 6 minutes. This service is run by the Department of Anaesthesiology and 
Pain Department of the Helen Joseph/Rahima Moosa Mother and Child Hospital Complex.  
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2.6 Summary
This chapter has been a discussion of current literature relevant to the study.  
Post operative pain is prevalent and not optimally managed.  There are many modalities for 
pain control.  The technique of a local anaesthetic continuous infusion in the incisional site 
for pain relief has not been used in South African public hospitals, one of the reasons being 
paucity of clinical evidence with this device.  Local anaesthetic infusions in the incisional 
site may improve the acute postoperative pain in these patients and be logistically possible 
as they are easier to manage and care for in the ward, compared to an epidural service.  
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3 Chapter Three:  Research Methodology
3.1 Introduction
In this chapter a detailed discussion of the methodology will be given. Points of discussion 
included are: problem statement, hypothesis, aim and objectives, ethical considerations, 
research methodology, financial considerations, the reliability and validity of the clinical 
study.  
3.2 Problem statement
At Rahima Moosa Mother and Child hospital it has been observed that pain is prevalent 
and poorly managed postoperatively in patients following total abdominable hysterectomy.  
A more effective pain management protocol needs to be introduced.  Morphine patient 
controlled analgesia is an effective pain relief option however there are concomitant opioid 
side effects.  The question arises whether a new technique of a bupivacaine infusion into 
the incisional site reduces pain and consequently decreases patients’ opioid requirements 
and therefore opioid side effects.
3.3 Hypothesis
There is no decreased pain intensity and/or decreased opioid consumption in patients with 
bupivacaine infusions into the incisional site compared to the control group.
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3.4 Aim 
The aim of the study is to determine whether there is a reduction in patients’ opioid 
requirements post total abdominable hysterectomy and a decrease in the patients’ pain 
intensity with the use of a bupivacaine infusion into the incisional site.
3.5 Objectives
The aims of the study will be justified by the following objectives.
3.5.1 Primary Objectives:
 To determine patients’ opioid consumption post total abdominal hysterectomy  in the 
presence of a local bupivacaine infusion incisional site
 To determine opioid consumption in patients’ post total abdominal hysterectomy 
without the presence of a local bupivacaine infusion in the incisional site 
 Compare the use of opioid consumption in the two above-mentioned groups of 
patients post total abdominal hysterectomy 
3.5.2 Secondary Objectives
 To determine patients’ post operative pain dynamic visual analogue scale (VAS) 
scores in patients post total abdominal hysterectomy  in the presence of a bupivacaine 
infusion in the incisional site at set time points
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 To determine patients’ post operative pain dynamic VAS scores in patients post total 
abdominal hysterectomy without the presence of a bupivacaine infusion in the 
incisional site at set time points 
 To compare the dynamic VAS scores between the two above mentioned groups
 To determine patients’ postoperative pain static VAS scores in patients post total 
abdominal hysterectomy  in the presence of a bupivacaine infusion in the incisional 
site at set time points
 To determine patients’ postoperative static VAS scores in patients post total 
abdominal hysterectomy without the presence of a bupivacaine infusion in the 
incisional site at set time points
 To compare the static VAS scores in the two above mentioned groups
 To determine the incidence of opioid adverse effects in patients post total abdominal 
hysterectomy  in the presence of a bupivacaine infusion in the incisional site at set 
time points
 To determine the incidence of opioid adverse effects in patients post total abdominal 
hysterectomy without the presence of a bupivacaine infusion in the incisional site at 
set time points 
 To compare the incidence of opioid adverse effects in the two above mentioned 
groups
3.6 Ethical considerations
3.6.1 Authorisation
An approval to conduct the study was obtained from the Ethics Committee of the 
University of the Witwatersrand, clearance number M070701 (Appendix A).
Approval by the Postgraduate Committee of the University of Witwatersrand was granted 
(Appendix B).
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Approval for the study was obtained by the hospital superintendent at the time and Head 
Matron of Rahima Moosa Mother and Child Hospital (Appendix C).
3.6.2 Patient Consent
Patients who met the selection criteria for this study were given a verbal explanation of the 
study and follow-up requirements by the clinical investigator.  Each patient was supplied 
with a copy of the Patient Information Form (Appendix D) and the Consent Form 
(Appendix E) which they read in their own time. Any questions and queries raised by the 
patient were answered appropriately by the researcher obtaining consent.  Patients that 
agreed to take part in the study gave written consent.  
The participants were made aware that participation/non-participation was not going to 
disadvantage them, directly or indirectly, in any way. 
3.6.3 Confidentiality of Subject Records
Confidentiality of subject data was maintained at all times.  Subject anonymity was 
guaranteed.  All documentation relating to the subject was kept in a secure location.  
Subjects were made aware that clinical data was stored electronically.
Confidentiality was guaranteed for any resulting publication. Subjects were made aware 
that data collected as part of this study may be published but anonymity was guaranteed.  
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3.6.4 Declaration of Helsinki
The World Medical Association Declaration of Helsinki and its subsequent amendments 
formed the accepted basis for the ethical conduct of this study (16).
3.6.5 Regulatory requirements
Regulatory approval was not required for this study as the infusion device and bupivacaine 
are commercially available.
3.7 Research methodology
3.7.1 Research design
This was a contextual, prospective, parallel, single blinded, randomised control trial. 
The study was contextual in nature as it was conducted in the Rahima Moosa Mother and 
Child Hospital.  It was prospective as the study examined the opioid consumption and 
visual analogue scale scores of women post total abdominable hysterectomy after 
participants gave their informed consent. The design was single blinded as the clinical 
providers and not the study participants knew who the control or trial participants were.
3.7.2 Study population
The study population for this study were women undergoing total abdominal hysterectomy 
at the Rahima Moosa Mother and Child Hospital, Johannesburg.
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3.7.3 Study Sample
3.7.3.1 Sample Statement
A biostatistician calculated that a sample size of at least 18 subjects per group would have 
power in excess of 90 % to detect a decrease of at least 20 milligrams over a time period of 
48 hours in morphine use using a one-sided t-test.  The standard deviation assumed was 
20mg which is the range of expected morphine use (10 – 130mg) divided by 6. The latter 
assumes a symmetric distribution, which is unlikely in this clinical study.
3.7.3.2 Sampling method 
A consecutive convenience sampling method was used in this study.  The most readily 
accessible elective gynaecological patients presenting for total abdominal hysterectomy 
surgery were included.  It is noted that a convenience sample cannot fully represent the 
study population.   The patients all had a routine general anaesthetic and standard analgesia 
intraoperatively.  
Every patient suitable for the clinical study who presented for the operation was invited to 
participate in the study.  Only patients who consented to take part in the study were 
included in the sample study.  Consecutive sampling is the most reliable for convenience 
sampling as research bias is limited (17).
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3.7.4 Selection criteria
Inclusion criteria 
 The following inclusion criteria were used for the study:
 ASA I-II patients
 Pfannenstiel incision only
 Informed consent to participate in this clinical study
Exclusion criteria
The following exclusion criteria were used for the study:
 Contraindication to general  anaesthesia
 Allergy to any of the study medications
 History of alcohol/drug abuse 
 Major medical disease such as cardiovascular, pulmonary, metabolic, renal, 
neurological or psychiatric disease
 Patients with clinically significant bacterial infection
3.7.5 Clinical Methodology
Patients scheduled for a total abdominal hysterectomy were assessed by the investigator 
pre-operatively. If the inclusion criteria were met, an informed consent to participate in the 
trial was obtained. 
Patients who consented to participate in this clinical study were randomly assigned to either 
receiving a bupivacaine infusion into their incisional site and a morphine patient controlled 
analgesia (PCA) pump, or to receive a morphine PCA pump only.  
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Preoperatively
The patients were preoperatively assessed the day before.  The anaesthetic orders were that 
the patient was to be starved appropriately and given no analgesic premedication.
Intraoperatively
The group of anaesthesiologists from the Helen Joseph/Rahima Moosa Mother and Child 
Hospital Anaesthetic Department, who provided the general anaesthetic for the study 
participants gave a uniform general anaesthesia with only opioid analgesia.  This was 
ensured with regular interactions with the researchers and presentations at departmental 
meetings.  
All patients had the standard monitors applied. Monitoring included non-invasive arterial 
blood pressure, heart rate, peripheral oxygen saturation, end-tidal gas monitoring and 
electrocardiogram.  After intravenous cannulation, anaesthesia was induced with opioids 
and propofol until loss of consciousness.  The opioids used were either fentanyl or 
alfentanil depending on the anaesthesiologist’s discretion.  The doses used were titrated to 
effect on the patient and varied accordingly.  Tracheal intubation was performed after 
muscle relaxation with a non depolariser muscle relaxant of the anaesthetists’ choice.  
Anaesthesia was maintained by an inhalational anaesthetic. Air and oxygen were used and 
the inhalational anaesthetic was either isoflurane or sevoflurane depending on the 
anaethesiologist’s discretion.  Mechanical ventilation was used in a low-flow system to 
maintain an end-tidal carbon dioxide of 35 – 45 mmHg.  Only opioids, namely fentanyl and 
morphine,  were given for analgesia.  Doses were titrated accordingly to the patients body 
mass and effect.   At the end of the operation, muscle relaxation was reversed with 
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glycopyrrolate and neostigmine in adequate doses and the inhalational anaesthetic was 
turned off.  After satisfactory spontaneous ventilation and awakening, the patient was 
extubated and transferred to the recovery area for further standard post-operation 
observations and facemask oxygen via a Venturi mask.  Once the recovery sisters were 
satisfied with the patients’ condition they discharged the patient to the ward where standard 
post operative observations were performed by the nursing staff.   
Surgery was performed by surgeons of five different surgical teams.  Surgery was 
preformed in a standardised manner using a Pfannenstiel incision, approximately 10-15cm 
depending on the patients body habitus.  Surgical procedures were either a total 
abdominable hysterectomy with or without salpingo-oophorectomy.  None of the 
participants had extensive blood loss requiring blood transfusion.
The patients who were study participants had an On-Q PainBusterR SoakerTM 6.5 pain 
relief system (all within their expiry date) inserted. At wound closure, a multi-holed
catheter (On-Q PainBusterR SoakerTM 6.5 pain relief system, 270ml volume, 4ml/hr, I-Flow 
Corporation, USA) was inserted by the gynaecologist along the length of the incisional site 
under the abdominal fascia.  Prior to the placement of these catheters 1-2ml bolus of 0.5% 
bupivacaine was injected into each catheter to prime them.  The placement method was as 
follows, the introducer needles were tunnelled 3-5cm lateral to the incision using a Z-track 
method.  A catheter was threaded through the introducer into the subfascial space.  The T-
peel was pulled out of the insertion site completely before been peeled away.  The catheter 
was brought out approximately 2cm away from the wound site. The fascial layer was 
closed with sutures over this catheter, after closure of the fascia the second catheter was 
inserted in a similar manner as the subfascial catheter but from the opposite side and above 
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the subfascial catheter.  Once the skin had been closed, 5ml bolus of 0.5% bupivacaine was 
injected through each catheter thus infiltrating the incision.  The catheters were secured by 
been coiled and taped to the skin with a dressing.  Using an aseptic technique, these 
catheters were then connected to a 270ml elastomeric disposable balloon pump with the 
appropriate volume of the study drug (192ml of 0.39% bupivicaine).  The drug infusion 
was started by opening the clamps on the catheter.  The bupivacaine was obtained from the 
pharmacy in a concentration of 0.5% (volume, 10ml/ampoule) all were within their expiry
date. This infusion was made up of 150ml of 0.5% bupivacaine (750mg) which was mixed 
with 42ml of 0.9% saline to provide 750mg bupivacaine in 192ml of 0.9% saline making 
up a concentration of 3.9mg/ml.  This was infused at 4ml/hr (15.6mg/hr) for 30hours.  An 
additional 10ml of 0.5% bupivacaine solution (50mg) was bolused down the catheters.  The 
total amount of bupivacaine injected during the 30 hours was 468mg which was within the 
manufacturers’ recommended dose of 400mg bupivacaine in a 24 hour period.
The control participants had after placing a sterile bandage over the wound site a catheter 
placed on top of the bandage and coiled and connected to apparatus similar to the trial 
group.  The catheter was taped and covered by another bandage.  The catheter neither 
penetrated the wound site nor infused any substance.   Both groups had the pump apparatus 
concealed in an On-Q painbuster black bag.
Postoperatively
After surgery, all patients were connected to morphine CADD-Legacy PCA Pump Model 
6300s (Smith Medical).  The PCA protocol was one milligram (1mg) morphine bolus dose 
with a lock-out of 6 minutes for breakthrough pain.  Maximum dose of morphine was 10 
milligrams per hour.  This concentration was made up from 90mg morphine diluted to 
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22ml of 0.9% saline making up a concentration of 4mg/ml.  This patient controlled 
analgesia (PCA) pump was for breakthrough pain. The patients were instructed in its use 
before surgery.  No other pain analgesia was prescribed.   If patients complained of nausea 
or vomiting, prochlorperazine 12,5mg intramuscularly was administered.  Promethazine 
25mg intramuscularly (8 hourly) was prescribed for patients with itchiness.
After thirty hours, the catheter was withdrawn and the intravenous line was taken down 
together with the morphine PCA pump. Regular diclofenac suppositories (100mg eighteen 
hourly) and paracetamol (1gr orally 6 hourly) was then prescribed for analgesia.
The patients were discharged by the surgical team.  
3.7.6 Data collection
Postoperative evaluations were performed by two assessors only (the researcher and an 
anaesthestic consultant) at 1 hour, 6, 24 and 30 hours post operation.  For all 
measurements, the time at which the study drug infusion was started was considered to be 
Time 0.  
The following postoperative evaluations at the set times were made:  Visual analogue pain 
scale (VAS) scores were for:-
 The worst pain experienced since the last observation
 Static pain intensity at the time of observation
 Dynamic pain intensity at the time of observation  
Opioid adverse effects, namely nausea, vomiting and itchiness were asked about at the set 
times post operation.  
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Total morphine consumption and the number of attempts for morphine boluses were 
recorded for the periods: 0-1hr, 1-6hrs, 6-24hrs and 24-30 hours post operation. 
Patient and nurse satisfaction with the catheter was also asked at each set time post 
operation.  The day of discharge and any perioperative complications were noted.  
Data was collected by the investigator in copy and compiled on a Microsoft Excel (2003) 
data table.
3.7.7 Data Collection Tool
The data sheet consisted of 2 sections (APPENDIX F):
Section A:  the demographic survey section included subcategories within the study sample 
by which data was analysed.  These subcategories were age and if the participants had 
previous Caesarean section(s).
Section B:  the subcategories were as follows - the worst pain intensity score felt since the 
previous set observation point, pain intensity scores when lying quietly (static VAS) and on 
movement (dynamic VAS), presence of adverse side-effects of morphine (itchiness, nausea 
and vomiting), any complications with the catheter, the patient’s satisfaction with the 
device, the nurses’ satisfaction with the device, day of hospital discharge and perioperative 
complications.
3.7.8 Study Devices
3.7.8.1 On-Q PainBusterR SoakerTM 6.5 pain relief system (figure 3.1)
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On-Q PainBusterR SoakerTM 6.5 pain relief system delivered the bupivacaine infusion in 
the incisional site as per the manufacturer’s guidelines. The infusion continued for a 30 
hour period at 4ml per hour.
  
Figure 3.1: ON-Q Pain BusterR SoakerTM 6.5 pain relief system (47)
3.7.8.2 CADD-Legacy PCA Pump Model 6300 (Smith Medical)
All participants were connected to a morphine CADD-Legacy PCA Pump Model 6300 
(Smith Medical) as per the morphine PCA protocol.
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3.7.9 Data Analysis
Data analysis was done in consultation with the biostatistician.  Descriptive statistics mean, 
standard deviation, median, range and 95% confidence intervals was employed to 
summarise the observed data that was morphine use and VAS scores.  Groups were 
compared using the two-sample t-test.  Also a Mann-Whitney U-test was employed for the 
skewed data   Testing was at the 0.05 level of significance.  A statistician assisted with the 
presentation and further analysis of the data collected. 
3.7.10 Statistical considerations
Function evaluation served as the basis for evaluating the clinical results of the subjects.
3.8 Costs
The participants in this study did not incur any extra costs.  Non-participation did not 
disadvantage participants in any way.
SA Biomedical Pty Ltd. supplied the 20 On-Q PainBusterR SoakerTM 6.5 pain relief 
systems. The analgesics were provided by the hospital pharmacy.
The CADD-Legacy PCA Pumps were the property of the Anaesthetic Department of the 
Rahima Moosa Mother and Child Hospital.  The components for the functioning of the 
morphine CADD-Legacy PCA Pump Model 6300 (Smith Medical) were provided by the 
hospital.  
Administrative costs were incurred by the Department of Anaesthesiology, Helen 
Joseph/Rahima Moosa Mother and Child Hospital Complex. 
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3.9 Validity 
The visual analogue scale is a well documented tool in measuring pain as a single quality 
that only varies in intensity.  The average group scores can be treated as ratio data and there 
is good evidence for validity (6).  In this study the individual scores were treated as ratio 
data.  
3.10 Reliability
The morphine PCA pumps were all programmed identically for all the study participants.  
The pumps programme was locked and was not adjusted while the participants were in the 
trial.
The On-Q PainBusterR SoakerTM 6.5 pain relief systems delivered the bupivacaine infusion 
in the incisional site as per the manufacturer’s guidelines.  The infusions were mixed and 
drawn up by only the two clinical investigators to ensure reliability. 
The data collection was collected consistently within the set data collection times.  The data 
was collected by only two investigators to ensure reliability.  
The amounts of morphine given and attempted were recorded from the morphine PCA 
computer which automatically recorded the number of attempts and amount of doses that 
the pump gave to the patient.
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3.11 Summary
The study design allowed for an assessment of the pain intensities of the study participants 
postoperatively in a single blinded fashion. The data collection sheet was a valid tool with 
increased standardisation as the data collected was by two assessors only. Thus allowing a 
comparison between the two groups in order to prove or disprove the hypothesis that there 
is no decreased pain intensity and/or decreased opioid consumption in patients with local 
bupivacaine infusions into the incisional site compared to the control group.
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4 Chapter Four:  Results and statistical analysis
4.1 Introduction
This chapter begins with the comparison of the demographic data between the two clinical 
trial groups.  It then continues with the results of the data collection and the statistical 
analysis.  The statistical analyses pertain to the two groups.  The results are the visual 
analogue scores and opioid consumption of the two groups at the set observation periods 
and the opioid adverse side effects at the set observation periods.  This is followed by the 
comparison of the two groups for statistical differences with one another.
4.2 Data Collection Results
4.2.1 Demographic Data and Analysis
The demographic data of the 2 groups illustrating the participants’ age, race, type of 
operation and body mass index follows.  
4.2.1.1  Age
The means, confidence intervals and standard deviations of the study participants’ ages are 
listed in Table 4.1.  These were for the control group 42.55 years of age, 38.21-46.80 and 
9.77 respectively.  The values for the device group were as follows 43.61 years of age, 
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39.96-47.26 and 7.34.  There were no missing values. The two sample t test with unequal 
variance result is 0.652.  This shows there was no statistical significance between the 
groups and their ages.
4.2.1.2  Racial comparison
The clinical data pertaining to the race group of the study participants is tabulated in Table 
4.2.  In the control group there were 15 Blacks, 6 “Coloureds”, 1 Indian making the number 
of 22 participants.  In the device group there were 12 Blacks, 4 “Coloureds” 1 Malay and 1 
White participant making up the number of 18 participants.  There were no missing values. 
The Fisher’s exact test result of 0.691 is noted. This indicates no statistical significance 
between the two groups.  
4.2.1.3 Operations of the study participants
The clinical data pertaining to the specific operations performed on the study participants is 
tabulated in Table 4.3.  In the control group there was 14 total abdominal hysterectomies 
(TAH), 7 total abdominal hysterectomies and bilateral salpingoophectomy (TAH and 
BSO), 1 myomectomy.  In the device group there were 10 TAHs, 7 TAH and BSO and 1 
total abdominal hysterectomy and unilateral salpingoophectomy (TAH and USO).  The 
Fisher’s exact test result of 0.721 is noted indicating no statistical significance between the 
two groups.
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4.2.1.4 Body mass index
The means, confidence intervals and standard deviations of the study participants’ ages are 
listed in Table 4.4.  These values in the control group were 28.79, 25.54-32.04 and 7.34 
respectively.  The values for the device group were as follows 31.12, 28.51-33.73 and 5.25.  
There were no missing values. The two sample t test with unequal variance result is 0.25.  
This test indicates no statistical difference between the two groups’ body mass indexes.
Table 4.1: Age comparison between the 2 groups
Group Observations Mean Standard 
error
Standard 
deviation
95% 
confidence 
interval 
(lower 
limit)
95% 
confidence 
interval 
(upper 
limit)
Control 22 42.55 2.08 9.77 38.21 46.80
Device 18 43.61 1.73 7.34 39.96 47.26
Combined 40 43.03 1.37 8.67 40.25 45.79
Difference -1.07 2.71 -6.54 4.41
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Table 4.2: Racial comparison between the 2 groups
Race Control Device Total
Black 15 12 27
Coloured 6 4 10
Indian 1 0 1
Malay 0 1 1
White 0 1 1
Total 22 18 40
Table 4.3: Operation comparison between the 2 groups
Operation Control Device Total
TAH 14 10 24
TAH & BSO 7 7 14
TAH & USO 0 1 1
Myomectomy 1 0 1
Total 22 18 40
TAH: total abdominal hysterectomy
TAH & BSO:  total abdominal hysterectomy and bilateral salpingoophectomy
TAH & USO: total abdominal hysterectomy and unilateral salpingoopherectomy
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Table 4.4: Body Mass Index
Group Observations Mean Standard 
error
Standard 
deviation
95% 
confidence 
interval  
(lower 
limit)
95% 
confidence 
interval 
(upper 
limit)
Control 22 28.79 1.56 7.34 25.54 32.04
Device 18 31.12 1.24 5.25 28.51 33.73
Combined 40 29.84 1.03 6.51 27.76 31.92
Difference -2.33 1.99 -6.365 1.70
4.2.1.5 Analysis of demographic data
The comparison of demographical information between the two groups and associated 
parametric and non parametric testing indicate there was no statistical difference between 
these two groups improving the validity of the results comparing the measured variables.
4.3 Descriptive statistical analysis of the data
The descriptive analyses will include the measured variables grouped at the set observation 
periods.
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4.3.1 Opioid consumption in the control group 
The means, confidence intervals and standard deviations of the opioid consumption of 
participants post total abdominal hysterectomy (TAH) without the device at the 4 different 
set observation periods are listed in Table 4.5.  There were no missing values.  The values 
for the Period 0-1 hour post operation are 4.89mg, 3-29-6.49mg and 3.6 mg respectively.  
The values for Period 1-6 hours post operation are 8.22mg, 5.43-11.02mg and 6.30mg 
respectively.  The values for Period 6-24 hours post operation are respectively 24.67mg, 
20.25-29.08mg and 9.70mg.  In the last period from 24 – 30 hours post operation the values 
are respectively 8.33mg, 6.12-10.49mg and 4.74mg.
4.3.2 Opioid consumption in the device group
The means, confidence intervals and standard deviations of the opioid consumption of 
participants post TAH with the device at the 4 different set observation periods are listed in 
Table 4.6.  There were no missing values.  The values for the Period 0-1 hour post 
operation are 3.35mg, 1.98-4.72mg and 2.67mg respectively.  The values for Period 1-6 
hours post operation are 10.83mg, 6.43-15.24mg and 8.86mg respectively.  The values for 
Period 6-24 hours post operation are respectively 25.11mg, 16.80-33.42mg and 16.71mg.  
In the last period from 24 – 30 hours post operation the values are respectively 5.78mg, 
3.52-8.03mg and 4.53mg.
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4.3.3 Dynamic visual analogue scale (VAS) scores in the device group 
The means, confidence intervals and standard deviations of the dynamic VAS scores of 
participants post TAH with the device at the 4 different set observation periods are listed in 
Table 4.7.  There were no missing values.  The values for the Period 0-1 hour post 
operation are 39.42, 21.36-57.47 and 36.31 respectively.  The values for Period 1-6 hours 
post operation are 33.97, 18.37-49.58 and 31.37 respectively.  The values for Period 6-24 
hours post operation are respectively 39.17, 25.16-53.17 and 28.16.  In the last period from 
24 – 30 hours post operation the values are respectively 32.56, 19.49-45.62 and 26.28.
4.3.4 Dynamic VAS scores in the control group
The means, confidence intervals and standard deviations of the dynamic VAS score of 
participants without the device at the 4 different set observation periods are listed in Table 
4.8.  There were no missing values.  The values for the Period 0-1 hour post operation are 
67.17, 54.20-80.13 and 28.49 respectively.  The values for Period 1-6 hours post operation 
are 48.73, 35.23-62.23 and 30.44 respectively.  The values for Period 6-24 hours post 
operation are respectively 60.89, 48.62-73.14 and 26.94.  In the last period from 24 – 30 
hours post operation the values are respectively 54.31, 40.07-68.54 and 31.28.
4.3.5 Static VAS scores in the device group
The means, confidence intervals and standard deviations of the static pain VAS score of 
participants with the device at the 4 different set observation periods are listed in Table 4.9.  
There were no missing values.  The values for the Period 0-1 hour post operation are 34.89, 
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17.27-52.51 and 35.44 respectively.  The values for Period 1-6 hours post operation are 
26.89, 13.20-40.58 and 27.52 respectively.  The values for Period 6-24 hours post operation 
are respectively 22.53, 14.46-30.59 and 16.22.  In the last period from 24 – 30 hours post 
operation the values are respectively 20.06, 8.54-31.57 and 23.16.
4.3.6 Static VAS scores in the control group
The means, confidence intervals and standard deviations of the static pain VAS score of 
participants without the device at the 4 different set observation periods are listed in Table 
4.10.  There were no missing values.  The values for the Period 0-1 hour post operation are 
59.25, 43.41-75.09 and 35.72 respectively.  The values for Period 1-6 hours post operation 
are 25.80, 17.59-34.00 and 18.51 respectively.  The values for Period 6-24 hours post 
operation are respectively 28.69, 15.69-41.69 and 28.56.  The last period from 24 – 30 
hours post operation the values are respectively 27.23, 16.75-37.72 and 23.03.
4.3.7 VAS scores of the worst pain since the last time seen in the control group 
The means, confidence intervals and standard deviations of the worst pain VAS score of 
participants without the device at the 4 different set periods are listed in Table 4.11.  There 
were no missing values.  The values for the Period 0-1 hour post operation are 72.45, 
60.12-84.79 and 27.83 respectively.  The values for Period 1-6 hours post operation are 
60.43, 46.61-74.45 and 31.62 respectively.  The values for Period 6-24 hours post operation 
are respectively 54.31, 41.24-67.38 and 28.72.  The last period from 24 – 30 hours post 
operation the values are respectively 45.90, 30.01-61.80 and 34.92.
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4.3.8 VAS scores of the worst pain since the last time seen in the device group
The means, confidence intervals and standard deviations of the worst pain VAS score of 
participants with the device at the 4 different set periods are listed in Table 4.12.  There 
were no missing values.  The values for the Period 0-1 hour post operation are 46.89, 
32.17-61.61 and 29.61 respectively.  The values for Period 1-6 hours post operation are 
35.86, 19.34-52.38 and 33.22 respectively.  The values for Period 6-24 hours post operation 
are respectively 50.53, 34.39-66.67 and 32.46.  The last period from 24 – 30 hours post 
operation the values are respectively 41.67, 23.94-59.39 and 35.64.
4.3.9 Opioid adverse effects in the device group and control group
The number of participants with opioid adverse effects namely nausea, vomiting and 
itchiness in the patients post TAH with the device.  The clinical data is tabulated in table 
4.13 with regard to the participants in the device group.  The clinical data is tabulated in the 
table 4.14 with regard to the participants in the control group.  In the first period 2 
participants from the device group complained of nausea or/and vomiting versus 4 control 
participants in the same period.  In the second period 6 participants in the device group 
complained of nausea and/or vomiting which was the same number in the control group.  In 
the third period 5 participants in the group with the device complained of nausea 
and/vomiting compared to 8 participants in the control group.  The last period 1 participant 
in the device group compared to 5 participants in the control group complained of nausea 
and/or vomiting.  
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In the first period 3 participants of the group with the device complained of itchiness 
compared to 1 participant in the control group.  In the second period 5 participants 
complained of itchiness compared to 1 participant in the control group.  In the third period 
8 participants from the device group compared to 10 participants in the control group 
complained of itchiness.  In the last period 10 participants from the device group compared 
to 11 participants in the control group complained of itchiness.  
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Table 4.5: Descriptive statistics of opioid consumption in the control group
Statistic Standard error
Period 0-1h mean
                    Standard deviation
                    95% Confidence level  lower limit
                                                          upper limit
4.89mg
3.60mg
3.29mg
6.49mg
0.77
Period 1-6h mean
                    Standard deviation
                    95% Confidence level  lower limit
                                                         upper limit
8.22mg
6.30mg
5.43mg
11.02mg
1.34
Period 6-24h mean
                      Standard deviation
                    95% Confidence level  lower limit
                                                          upper limit
24.67mg
9.70mg
20.25mg
29.08mg
2.12
Period 24-30h mean
                       Standard deviation
                   95% Confidence level  lower limit
                                                         upper limit
8.33mg
4.74mg
6.12mg
10.49mg
1.03
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Table 4.6: Descriptive statistics of opioid consumption in the device group
Statistic Standard error
Period 0-1h  mean
                     Standard deviation
                     95% Confidence level  lower limit
                                                           upper limit
3.35mg
2.67mg
1.98mg
4.72mg
0.65
Period 1-6h mean
                    Standard deviation
                    95% Confidence level  lower limit
                                                          upper limit 
10.83mg
8.8g6m
6.43mg
15.24mg
2.1
Period 6-24h mean
                      Standard deviation
                      95% Confidence level  lower limit
                                                          upper limit
25.11mg
16.71mg
16.80mg
33.42
3.94
Period 24-30h mean
                       Standard deviation
                       95% Confidence level  lower limit
                                                            upper limit
5.78
4.53
3.52
8.03
1.07
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Table 4.7: Descriptive statistics of dynamic VAS scores in the device group
Statistic Standard error
Period 0-1h  mean
                     Standard deviation
                     95% Confidence level  lower limit
                                                           upper limit
39.42
36.31
21.36
57.47
8.56
Period 1-6h mean
                    Standard deviation
                    95% Confidence level  lower limit
                                                          upper limit
33.97
31.37
18.37
49.58
7.40
Period 6-24h mean
                      Standard deviation
                      95% Confidence level  lower limit
                                                          upper limit
39.17
28.16
25.16
53.17
6.63
Period 24-30h mean
                       Standard deviation
                       95% Confidence level  lower limit
                                                            upper limit
32.56
26.28
19.49
45.62
6.19
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Table 4.8: Descriptive statistics of dynamic VAS scores in the control group
Statistic Standard error
Period 0-1h  mean
                     Standard deviation
                     95% Confidence level  lower limit
                                                           upper limit
67.17
28.49
54.20
80.13
6.21
Period 1-6h  mean
                    Standard deviation
                    95% Confidence level  lower limit
                                                          upper limit
48.73
30.44
35.23
62.23
6.49
Period 6-24h mean
                      Standard deviation
                      95% Confidence level  lower limit
                                                           upper limit
60.89
26.94
48.62
73.14
5.88
Period 24-30h mean
                       Standard deviation
                       95% Confidence level  lower limit
                                                            upper limit
54.31
31.28
40.07
68.54
6.82
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Table 4.9: Descriptive statistics of the static VAS scores in the device group
Statistic Standard error
Period 0-1h  mean
                     Standard deviation
                     95% Confidence level  lower limit
                                                           upper limit
34.89
35.44
17.27
52.51
8.35
Period 1-6h mean
                    Standard deviation
                    95% Confidence level  lower limit
                                                          upper limit
26.89
27.52
13.20
40.58
6.49
Period 6-24h mean
                      Standard deviation
                      95% Confidence level  lower limit
                                                          upper limit
22.53
16.22
14.46
30.59
3.82
Period 24-30h mean
                       Standard deviation
                       95% Confidence level  lower limit
                                                            upper limit
20.06
23.16
8.54
31.57
5.46
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Table 4.10: Descriptive statistics of static VAS scores in the control group
Statistic Standard error
Period 0-1h  mean
                     Standard deviation
                     95% Confidence level  lower limit
                                                           upper limit
59.25
35.72
43.41
75.09
7.62
Period 1-6   mean
                    Standard deviation
                    95% Confidence level  lower limit
                                                          upper limit
25.80
18.51
17.59
34.00
3.95
Period 6-24h mean
                      Standard deviation
                      95% Confidence level  lower limit
                                                          upper limit
28.69
28.56
15.69
41.69
6.23
Period 24-30h mean
                       Standard deviation
                       95% Confidence level  lower limit
                                                            upper limit
27.23
23.03
16.75
37.72
5.03
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Table 4.11: Descriptive statistics of the VAS score of the worst pain since the last time 
seen in the control group
Statistic Standard error
Period 0-1h  mean
                     Standard deviation
                     95% Confidence level  lower limit
                                                           upper limit
72.45
27.83
60.12
84.79
5.93
Period 1-6h mean
                    Standard deviation
                    95% Confidence level  lower limit
                                                          upper limit
60.43
31.62
46.41
74.45
6.74
Period 6-24h mean
                      Standard deviation
                      95% Confidence level  lower limit
                                                          upper limit
54.31
28.72
41.24
67.38
6.27
Period 24-30h mean
                       Standard deviation
                       95% Confidence level  lower limit
                                                            upper limit
45.90
34.92
30.01
61.80
7.62
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Table 4.12: Descriptive statistics of the VAS score of the worst pain since the last time 
seen in the device group 
Statistic Standard error
Period 0-1h  mean
                     Standard deviation
                     95% Confidence level  lower limit
                                                           upper limit
46.89
29.61
32.17
61.61
6.98
Period 1-6h mean
                    Standard deviation
                    95% Confidence level  lower limit
                                                          upper limit
35.86
33.22
19.34
52.38
7.83
Period 6-24h mean
                      Standard deviation
                      95% Confidence level  lower limit
                                                          upper limit
50.53
32.46
34.39
66.67
7.65
Period 24-30h mean
                       Standard deviation
                       95% Confidence level  lower limit
                                                            upper limit
41.67
35.64
23.94
59.39
8.40
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Table 4.13: Opioid adverse effects in the device group
Nausea/vomiting Itchiness total
No Yes No Yes
Period 0 -1h 16 2 15 3 18
Period 1-6h 12 6 13 5 18
Period 6 – 24h 13 5 10 8 18
Period 24 – 30h 17 1 8 10 18
Table 4.14: Opioid adverse effects in the control group
Nausea/vomiting Itchiness total
No Yes No   Yes
Period 0-1h 18 4 21 1 22
Period 1-6h 16 6 20 2 22
Period 6–4h 13 8 11 10 21
Period 24–30h 16 5 10 11 21
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4.4 Analysis for statistical differences between the control and device 
groups
The opioid consumption of the two groups and the VAS scores of the two groups at set 
observation periods were tested with the two sample t test with unequal variances and two-
sample Wilcoxon rank-sum (Mann-Whitney) tests.  They were both used to increase the 
reliability of the results.  The measured variables were analysed and illustrated in the 
following order:  opioid consumption between the control and device group, dynamic VAS 
scores between the control and device groups, the static VAS scores between the control 
and device group and the worst VAS score since the last time seen since the control and 
device group. 
The non continuous variables namely the opioid adverse effects (nausea, vomiting and 
itchiness) were tested with the Fischer exact test.  The data is analysed following the 
continuous variable data analysis.  The comprehensive statistical data and tables are in 
Appendix H.
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4.4.1 Opioid consumption between the control and device groups 
Analysis of the opioid consumption was performed.  There was no statistical difference 
between the two groups. The following p values are when equal variance is assumed and 
then tested again for unequal variance respectively. The p value at the first set period was 
0.134 and 0.145.  The p value at the second set period was 0.302 and 0.369.  At the third 
set period the p value was 0.922 and 0.544 and the last set period the p values were 0.094 
and 0.090 respectively.  Figure 4.1 is a line graph illustrating the differing opioid 
consumption of the participants at the set observation periods.
Figure 4.1: Comparison of morphine consumption between the device and control 
groups
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4.4.2 Dynamic VAS scores between the control and device groups
Analysis for statistical difference between the dynamic VAS scores of the two groups was 
performed.  First, equal variance was assumed and then the data was tested for unequal 
variance. There was a statistical difference between the two groups at the first, third and 
fourth set observation period.  The p value at the first set period was 0.013 and 0.021.  The 
p value at the second set period was 0.142 and 0.097.  At the third set period the p values 
were 0.019 and 0.022 and the last set period the p values were 0.023 and 0.047.  This is 
illustrated in Figure 4.2 with the significant p values asterisked.
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  Figure 4.2: Dynamic VAS scores in the two groups 
                     *p=0.013  **p=0.019  ***p=0.023
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4.4.2 Static VAS scores between the control and device group
Analysis of the static VAS scores was performed.  First, equal variance was assumed and 
then the data was tested for unequal variance. There was a statistical difference between the 
two groups at the first set observation period.  The p value at the first set observation period 
was 0.038 and 0.048.  The p value at the second set period was 0.887 and 0.596.  At the 
third set period the p value was 0.405 and 0.921 and the last set period the p values were 
0.339 and 0.231. These numbers are depicted in the Figure 4.2 below with the statistically 
significant p value asterisked.
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Figure 4.3: Static VAS scores of the control and device groups
                   *p=0.038
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4.4.3 Worst VAS since the last time seen between the device and control groups
Analysis of the worst VAS scores since the last time observed was done. Equal variance 
was first assumed and then the data was tested for unequal variance.  There was a statistical 
difference between the two groups at the first and second set periods.  The p value at the 
first set period was 0.008 and 0.010.  The p value at the second set period was 0.023 and 
0.020.  At the third set period the p value was 0.704 and 0.583 and the last set period the p 
values were 0.711 and 0.693 respectively.  This data is illustrated in Figure 4.4 with the 
significant p values asterisked.
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Figure 4.4: VAS for the worst pain experienced since last seen between the device and 
control groups
* p= 0.008  **p=0.023
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4.4.4 Opioid adverse effects between the control and device groups
This categorical data between the device and control groups was analysed with the 
Fischer’s exact test. 
4.4.4.1 Nausea and vomiting between the control and device groups
The incidence of nausea and vomiting between the two groups showed no statistical 
difference.  The Fischer’s exact test at the first set period was 0.673, the second set 
observation period 0.738, third set observation period 0.734 and fourth set observation 
period was 0.190.
Figure 4.5: Comparison of the two groups:  incidence of nausea and vomiting
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4.4.4.2 Itchiness between the control and device groups
There was no statistical difference between the two groups.  The Fischer’s exact test at the 
first set period was 0.310, second period 0.211, third period 1.000 and fourth set period was 
1.000.
Figure 4.6: Comparison of the two groups: incidence of itchiness 
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4.5 Conclusion
Chapter four gives a comprehensive analysis of the data obtained in this clinical study.  The 
analysis was performed in a manner to answer the primary and secondary objectives of this 
study.
In summary, the two groups had a similar demographic profile to ensure validity of the 
study findings.  Statistical differences were seen between the control and device groups’ 
VAS scores in the first period and worst VAS scores in the second set observation period.  
There were statistically lower dynamic VAS scores in the device group compared to the 
control group in the third and fourth set periods.  
There was no statistical difference between the two groups’ opioid consumption and 
adverse side effects.
Chapter 5 will follow with the discussion and recommendations of the findings of this 
chapter.
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5 Chapter 5:  Discussion and Recommendations
5.1 Introduction
This chapter has a detailed discussion on the results and findings of the clinical study.  
From this is a discussion on the implications of daily practise and further research.  
Following this is the conclusion regarding the hypothesis of decreased pain intensity and/or 
opioid consumption in patients with bupivacaine infusions into the incisional site post total 
abdominal hysterectomy.  
5.2 Discussion of statistical results
The two clinical study groups had a similar demographic profile to ensure validity of the 
measured study findings.  
Statistical differences were seen between the two groups’ dynamic VAS scores in the first 
(1 hour post operation), third (24 hours post operation) and fourth (30 hours post operation) 
observation periods.  There was also a statistical difference in the static VAS score in the 
first observation period.  Thirdly there was a statistical difference in the worst VAS scores 
in the first and second observation periods.
  
The mean dynamic VAS score of the device group in the first, third and fourth periods 
were 39.42, 39.17 and 35.36 respectively.  This is in comparison with the mean dynamic 
72
VAS scores of the control group in the first, third and fourth periods which were 67.17, 
60.89 and 54.31 respectively.  The p values were 0.013, 0.019 and 0.023 respectively.  
The mean worst VAS score of the control group in the first and second observation period 
was 72.45 and 60.43 respectively, this is compared with the mean worst VAS score of the 
device group of 46.89 and 35.86 respectively.  The p values were 0.008 and 0.023 
respectively making these results statistically significant.  
The mean static VAS score of the device group in the first period was 34.89 compared to 
the mean static VAS score of the control group as 59.25.  This resulted in a statistically 
significant p value of 0.038.
Movement of a patient elicits somatic pain more than visceral pain.  The decrease in 
dynamic VAS scores could reflect that the bupivacaine infusion decreased the somatic pain 
from the incisional site.  In contrast, the static VAS scores were not different from 6 hours 
post operation as the bupivacaine infusion did not provide any pain relief from the visceral 
component originating mainly from the peritoneum.
There was no statistical difference between the two groups’ opioid consumption and 
adverse side effects namely nausea, vomiting and itchiness.
The mean opioid consumption in the device group in the first, second, third and fourth 
periods was the following 3.35mg, 10.83mg, 25.11mg and 5.78mg.  This is compared to 
the mean opioid consumption in the control group of the respective observation periods as 
been 4.89mg, 8.22mg, 24.67mg and 8.33mg.  
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The reason for the difference between the two trial groups in their VAS scores but similar 
opioid consumption could be speculated that the bupivacaine infusion helped relieve 
somatic pain from the incisional site but not the visceral component of pain post operation 
which needed morphine boluses to help ease.  In addition, the morphine PCA is still a 
relatively novel device in the government setting, and nurses might be overenthusiastic in 
their instruction to the patients to “push the button”. Finally, communication between the 
researchers and patients of different home languages could have caused differences in 
understanding of when to push the button for pain relief. 
The documented occurrence of the opioid adverse effects namely itchiness, nausea and 
vomiting, between the two groups was also not statistically different either.  However, the 
sample size is small and so the number of participants (that is the counts) were used and not 
the percentages.
The visual analogue scale score is an unidimensional instrument using the patients’ self-
reported assessment of the intensity of pain.  This pain measurement tool indicated that 
patients in the device group reported less intensity of pain in the above mentioned set 
periods than the participants in the control group.  The VAS score did not correlate with the 
participant’s opioid consumption.  There was no significant difference between the groups’  
morphine consumption and the incidence of morphine’s adverse effects.   
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5.3 Discussion of limitations and logistical issues
 The study population was not representative of the national group of women undergoing 
total abdominal hysterectomy in South Africa.  However the study sample addressed a 
clinical setting that is relevant locally, that is the Rahima Moosa Mother and Child 
Hospital.  This is a public hospital in central Johannesburg surrounds.
The clinical setting of the study resulted in single blinded conditions whilst evaluations 
were performed.  That is the patients did not know whether they had the bupivacaine 
infusion in their incisional site or not (as all participants had the same external apparatus), 
however the researchers and surgeon did.  Scientific methods required placing a subfascial 
catheter in all participants, evident ethical reasons restrained our application of this method.  
Bias may have occurred due to the design of the trial, not been double-blinded. 
The application of the subfascial catheter prolonged the anaesthetic time minimally and the 
surgeons found the technique of inserting the catheters simple.  The time required in 
insertion of these catheters was less than five minutes.  There was one complication with 
the subfascial catheter and this was that on insertion of the first catheter the surgeon 
transacted it with the scalpel.  It was noted immediately and the catheter parts were 
removed and replaced with a complete catheter with no further problems.  
The participants were strongly positive concerning their pain relief management plan 
especially the high level of satisfaction obtained with the self administration of opioid 
boluses for their pain relief.  Three participants complained of only back pain (two device 
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participants, one control participant).  A participant in the device group commented: “I 
don’t know what it is but it is fantastic”.
The device group reported no adverse effects or hindrances regarding the elastomeric 
pump.  The nursing staff in the recovery holding area and wards required only basic 
education and training in the use of these pumps. They were highly satisfied with the use of 
these elastomeric pumps and required minimal re-education.  The nurses on the whole felt 
that the standard of patient care of the participants was increased and felt that there was no 
extra nursing burden concerning the care of the elastomeric pumps and its application.
The application of these elastomeric pumps did not require similar extensive training or 
more nursing requirements for patient care such as in situations when neuroaxial analgesia 
is been performed.  
  
Technical problems of running an intravenous line for adequate PCA management 
occurred.  These were rectified easily by either of the two researchers or nursing staff but 
did require a delay in administered morphine boluses. These were:  high pressure alarms -
the PCA clamp had been mistakenly clamped (two incidents), leaking of the intravenous 
lines - managed successfully with tightening of the intravenous connections (two 
incidents), dislodgement and blocking of the intravenous access port which required 
resiting of the intravenous line.  In total eight intravenous lines needed to be resited due to 
migration of catheters into subcutaneous tissues.  
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Participants were mobilised as soon as possible and all participants were mobilised twenty-
four hours post operation. The participants found the intravenous line administration set 
and the PCA pump itself as bulky equipment and cumbersome.  Some participants 
commented that this was a hindrance to mobilisation.  
The intravenous fluid administration was continued to prevent the line becoming blocked.  
The intravenous fluid was not administered at a strict flow rate, this could have resulted in 
excess fluid given and three participants (2 controls) complained of excessive urinary 
micturition.  The routine management plan for these patients post total abdominal 
hysterectomy in this hospital was that the intravenous line was removed twenty-four hours 
post operation.  Due to the circumstances of the study the intravenous line remained so the 
PCA pump could be continued.  Four participants were unhappy or complained of pain due 
to the intravenous access. 
The incidence of adverse effects of opioids was overall low but two participants in the 
control group complained of itchiness severe enough to be treated with a promethazine 
injection. 
Generally the surgical teams were happy with the patient outcomes regarding postoperative 
pain.  A feedback questionnaire (appendix G) was distributed after the completion of the 
clinical study.  The surgical teams consisted of consultants, registrars and interns.  They all 
thought that the PCA pumps benefited the patients with the reasons been patients had less 
perceived pain, more satisfaction and better quality of analgesia.  The doctors noted that 
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there had been some problems with the intravenous lines required for the management of 
the PCA pumps as mentioned earlier. 
The self application of the PCA pump required patient understanding which is hampered by 
patients with language barriers or cultural differences.  Constant application of analgesia 
such as an elastomeric pump in these instances could provide better pain analgesia. 
5.4 Implications in daily practice
The continuous bupivacaine infusion in the incisional site increases the options for 
postoperative pain relief.  From this study it is noted that participants with the bupivacaine 
infusion had decreased pain intensities in the first hour post operation.  The participants 
also had a decreased level of dynamic pain intensity in three of the four time periods and 
lastly decreased worst pain intensity up to six hours post operation.  This pain relief option 
could provide better pain analgesia but not reduce patients’ opioid consumption.  Faster 
recovery and earlier discharge from hospital care was not investigated.  Pain relief devices 
that do not employ intravenous access will possibly provide better patient satisfaction as 
are less cumbersome.  However the pain relief of these elastomeric pumps in the incisional 
wound may only relieve the somatic component of the pain post operation and not the 
visceral component. 
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5.5 Implications in future research
Pfannenstiel incisions cover about 2-3 dermatomes, whereas midline incisions cover 
several dermatomes.  It can be postulated that the incisional bupivacaine infusion will 
benefit patients more who undergo midline incisions.  Studies in South Africa have not 
been carried out in this group of patients. 
The VAS score does not correlate with the participant’s opioid consumption.  This should 
be further investigated and evaluated. This might be due to the VAS score reflecting 
somatic and visceral pain components rather than just the somatic component which the 
bupivacaine infusion was most likely providing analgesia for in the incisional site.  
Limitations of this pain score for post operation pain  should be further elucidated and 
investigated. 
5.6 Conclusion and summary
This chapter reviewed and discussed the statistical analysis of the data collected.  It also 
discussed the logistical and practical issues of the elastomeric pump and PCA pumps in 
postoperative pain management.
Statistical analysis of the pain intensity scores and opioid consumption in participants who 
had a bupivacaine infusion in the incisional site shows that these participants had less pain 
intensity scores of varying types at different observation periods but no difference in opioid 
consumption between the control group and device group.  The study does therefore refute 
the hypothesis that there is no decreased pain intensity in patients with bupivacaine 
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infusions into the incisional site post total abdominal hysterectomy, however does support 
the hypothesis that there is no difference in opioid requirements compared to the control 
group.  Because the data collected was reliable and valid, the findings and hence 
implications, for the use of a bupivacaine infusion in the incisional site post total abdominal 
hysterectomy in South Africa is clinically important and relevant.
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6 Appendix A:  Ethics clearance certificate
Please note that the title was changed and approved by the Postgraduate Committee in 
September 2009.
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Appendix C:  Patient information Pamphlet
Information leaflet and informed consent
STUDY NUMBER:
STUDY TITLE:  Does a bupivacaine infusion into the incisional site reduce opioid 
requirement post total abdominal hysterectomy.
INVESTIGATOR: DR SAMANTHA RUSSELL
INSTITUTION: CORONATION HOSPITAL – now know as the Rahima 
Moosa Mother and Child Hospital
DATE AND TIME OF FIRST INFORMED CONSENT DISCUSSION
Dd Mm yyyy
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INTRODUCTION
Good day, my name is Dr Russell; I am a registrar in Anaesthesiology at Helen Joseph and 
Coronation Hospital.  I would like to invite you to be part of a research study entitled; Does 
a bupivacaine infusion into the incisional site reduce opioid requirement post total 
abdominal hysterectomy.       
1.  Before agreeing to participate, it is important that you read and understand the reason 
for the study, the study procedures, as well as the alternative procedures that are available 
to you. You have the right to withdraw from the study at any time. This information leaflet 
is to help you to decide if you would like to participate.  You should fully understand what 
is involved before you agree to take part in this study     
2.  If you have any questions, do not hesitate to ask me.
3.  You should not agree to take part unless you are satisfied about all the procedures 
involved.
4.  Please be completely truthful with me regarding your health history.
5.  If you decide to take part in this study, you will be asked to sign this document to 
confirm that you understand the study.  You will be given a copy to keep.
PURPOSE OF THE STUDY
You have been booked for an operation to remove your uterus/womb.
 I would like you to consider taking part in this study where we use a new pain control 
device. We want to see if this method will provide better pain relief for you after the 
operation and whether you will need less morphine to control the pain after the operation.
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You will be randomly allocated to one or another group (i.e. like spinning a coin).  This 
procedure helps to ensure that the information gathered during the study is accurate.
The study group will have a tube in the wound and the other group will not.  Both groups 
will have the best treatment available for us at the moment, to control the pain. If you want 
to stop the trial at any stage you can do so without any harm to yourself 
LENGTH OF STUDY AND NUMBER OF PARTICIPANTS:
The study will be performed in Coronation Hospital, Johannesburg.  Approximately 40 
patients will be involved in this study.  The total amount of your time required for this 
study will be a maximum of 3 days. I will visit you about 6 times during the study.
PROCEDURES:
If you agree to take part in this study, you will first be asked questions and examined to see 
if you qualify for this study. 
At the end of the operation while you are still asleep we will attach a patient controlled pain 
pump to your drip. Every time you have pain you press a button and a small amount of 
morphine goes into your bloodstream for pain relief. You can not give yourself too much 
morphine with this device and you should use it as much as you want.
If you are in the study group the surgeon will insert a tube in the wound site and connect it 
to another pump.  This pump is filled with a pain-killer.  You can move around with the 
pump with no added discomfort.  A tiny tube connects to the pump.  The flow of 
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medication into the wound is carefully controlled. There is no need to squeeze or adjust it.  
As the medicine is released, the pump will get smaller.  .    
At each visit I will ask you about your pain and whether you have any side effects such as 
nausea, vomiting and itching.  You will also be asked if you are satisfied with the tube.
WILL ANY OF THESE STUDY PROCEDURES RESULT IN DISCOMFORT OR 
INCONVENIENCE?
The pump must not get wet, so while you are washing please keep the pump dry in a plastic 
bag.  The catheter may fall out accidentally.
RISKS OF THE STUDY MEDICINE:
Some participants may experience adverse effects to the medication   You need to call your 
doctor immediately if you experience any of the following:
Redness, warmth where the tube enters your skin
Ringing, buzzing in your ears
Numbness and/or tingling around your mouth, fingers or toes
These occurrences are very rare, but could happen if you are sensitive to the local 
anaesthetic, get too much of it, or if the catheter has moved out of its correct place. 
UNFORSEEN RISKS:
This device has been used for more than ten years overseas (in Scandinavia, Canada and 
the USA), but this is the first time it has been used in South Africa in government hospitals. 
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We do not anticipate any side-effects other than those listed above, but should anything 
untoward occur, please let the ward sister know immediately, and she will contact me at 
once.
BENEFITS:
The potential benefit from your participation in this study may be:-
Less pain
Continuous pain relief
Faster return to normal activities
Quicker return to normal body function
Clear and groggy-free head
Greater mobility
More comfortable recovery
Less morphine side-effects such as nausea, vomiting, breathing problems, constipation, 
groggy, ‘hangover’ feeling
However you may not benefit from this study.  Your participation in this study will 
contribute to medical knowledge that may help other patients that, like you, when they 
have an operation  
ALTERNATIVE TREATMENT:
Alternative treatment is in the form of the usual postoperative pain relief given to patients 
who have the same operation at this hospital.  If you decide not to take part in this study 
89
you will still receive the usual care and treatment given in this hospital by your usual 
doctor. 
BENEFITS AND RISKS OF STANDARD ALTERNATIVE TREATMENT:
The standard treatment is injection, tablets and suppositories. 
ARE THERE ANY WARNINGS OR RESTRICTIONS CONCERNING MY 
PARTICIPATION IN THIS STUDY?
You should not participate in this study if you know that you are allergic to Local 
anaesthetic. (This is a very rare condition.) The catheter and the study medicine will be 
removed on day 2 and will not restrict your daily activities, however if you take a shower 
or bath before this time, please make sure that the device and the catheter stay dry.
INTERACTIONS
It is important that you let me know of any medicines (both prescription and over-the-
counter medicines), alcohol or other substances that you are currently taking.  During this 
study, you should not take any other pain medicine or alcohol.  If you have to, please 
inform me immediately.
RIGHTS AS A PARTICIPANT IN THIS STUDY:
Voluntary: Your participation in this study is entirely voluntary and you can decline to 
participate, or stop at any time, without stating any reason.
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Discontinuation of study treatment:  You must inform me if you wish to stop using the 
pump before the three days are up.  I will make sure this is done correctly. 
Withdrawal:  If you decide to withdraw we will continue to give you the best care possible
NEW FINDINGS
I will provide you with any additional information that becomes available during the study, 
which may affect your willingness to continue with the study.
FINANCIAL ARRANGEMENTS
There are no additional costs involved for you in this study; all the costs will be borne by 
the company that is providing the pain pump and the Department of Anaesthesiology, 
Helen Joseph/Coronation Hospital Complex.
ETHICAL APPROVAL
This clinical study protocol has been submitted to the University of the Witwatersrand, 
Human Research Ethics Committee (HREC) and written approval has been granted by that 
committee.
The study has been structured in accordance with the Declaration of Helsinki (last updated: 
October 2000), which deals with the recommendations guiding doctors in biomedical 
research involving human participants.  A copy may be obtained from me should you wish 
to review it.
The tubes are supplied by SA Biomedical Services.   I do not have any financial or personal 
interest with this organisation that may bias my actions.
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SOURCE OF ADDITIONAL INFORMATION
For the duration of the study, you will be under the care of your gynaecologist, ward 
nursing staff and me with regards to your postoperative pain management.  If at any time 
between your visits, you feel that any of your symptoms are causing you any problems, or 
you have any questions during the study, please do not hesitate to contact me.  
Other doctors from this department who are working on this study are:
Dr E Frohlich; Departmental Head of Anaesthesiology and Pain Specialist
Dr P du Plessis:  Consultant Anaesthesiologist
The 24-hour telephone number, which you can reach me is 079 5292505.
If you want any information regarding your rights as a research participant, or complaints 
regarding this research study, you may contact Prof.  Cleaton-Jones, Chairperson of the 
University of the Witwatersrand, Human Research Ethics Committee (HREC), which is an 
independent committee established to help protect the rights of research participants at 
(011) 717 2229.
CONFIDENTIALITY
All information obtained during the course of this study, including hospital records, 
personal data and research data will be kept strictly confidential.  Data that may be reported 
in scientific journals will not include any information that identifies you as a participant in 
this study.
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This information will be reviewed by authorised researchers.
The information might also be inspected by the University of the Witwatersrand, Human 
Research Ethics Committee (HREC), as well as your personal doctor.  Therefore, you 
hereby authorise me to release your medical records to me as well as University of the 
Witwatersrand, Human Research Ethics Committee (HREC) (if necessary).
These records will be utilised by them only in connection with carrying out their 
obligations relating to this clinical study.  Any information uncovered regarding your test 
results or state of health as a result of your participation in this study will be held in strict 
confidence.  You will be informed of any finding of importance to your health or continued 
participation in this study but its information will not be disclosed to any third party 
without your written permission.  
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9 Appendix D:  Consent Form
INFORMED CONSENT
I hereby confirm that I have been informed by the study doctor, Samantha Russell, about 
the nature, conduct, benefits and risks of this clinical study Does a bupivacaine infusion 
into the incisional site reduce opioid requirement post total abdominal hysterectomy.
I have also received, read and understood the above written information (Participant 
Information Leaflet) regarding the clinical study.
I am aware that the results of the study, including personal details regarding my sex, age, 
date of birth, initials and diagnosis will be anonymously processed into a study report.
In view of the requirements of research, I agree that the data collected during this study can
be processed in a computerised system by me.
I may, at any stage, without prejudice withdraw my consent and participation in the study.
I have had sufficient opportunity to ask questions and (of my own free will) declare myself 
prepared to participate in the study.
PARTICIPANT
_______________       _______________________             _________________
Printed Name Signature/Mark or thumbprint Date and Time
I, Samantha Russell, herewith confirm that the above participant has been fully informed 
about the nature, conduct and risks of the above study.
_____________                      ___________________          _________________
Printed Name Signature Date and Time
TRANSLATOR/OTHER PERSON EXPLAINING INFORMED CONSENT (if 
applicable):
_____________                 _________________                  _________________
Printed Name Signature Date and Time
WITNESS (designation):
 ___________________________________________________________________
Printed Name Signature Date and Time
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10 Appendix E:  Data Collection Tool
Study number:
A:  Age: Previous Caesarean sections:
B: 1 hour post operation
Are you experiencing pain now? YES  NO 
On this scale, please indicate the worst pain you have had in the past 24 hours
0-----------------------------------------------------------------------------------100  
No pain Worst pain possible
On this scale, please indicate the pain you experience when you are in bed
0-----------------------------------------------------------------------------------100  
No pain Worst pain possible
On this scale, please indicate the pain you experience when you cough/move
0-----------------------------------------------------------------------------------100  
No pain Worst pain possible
Are you experiencing itchiness? YES  NO 
Have you felt nauseous or vomited in the past 4 hours? YES  NO 
Amount of IV morphine given:  
Satisfaction with catheter? YES  NO 
Any complications with catheter (dislodgement, signs of infection)
NO   YES  Please detail:  
Nurses’ satisfaction with catheter YES  NO 
Comments
6 hours postoperative
Are you experiencing pain now? YES  NO 
On this scale, please indicate the worst pain you have had in the past 24 hours
0-----------------------------------------------------------------------------------100 
No pain Worst pain possible
On this scale, please indicate the pain you experience when you are in bed
0-----------------------------------------------------------------------------------100  
No pain Worst pain possible
On this scale, please indicate the pain you experience when you move/cough
0-----------------------------------------------------------------------------------100  
No pain Worst pain possible
Are you experiencing itchiness? YES  NO 
Have you felt nauseous or vomited in the past 6 hours? YES  NO 
Amount of IV morphine given:  
Satisfaction with catheter? YES  NO 
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Any complications with catheter (dislodgement, signs of infection)
NO   YES  Please detail:  
Nurses’ satisfaction with catheter YES  NO 
Comments
24 hours postoperative
Are you experiencing pain now? YES  NO 
On this scale, please indicate the worst pain you have had in the past 24 hours
0-----------------------------------------------------------------------------------100  
No pain Worst pain possible
On this scale, please indicate the pain you experience when you are in bed
0-----------------------------------------------------------------------------------100  
No pain Worst pain possible
On this scale, please indicate the pain you experience when you move/cough
0-----------------------------------------------------------------------------------100  
No pain Worst pain possible
Are you experiencing itchiness? YES  NO 
Have you felt nauseous or vomited in the past 18 hours? YES  NO 
Amount of IV morphine given:  
Satisfaction with catheter? YES  NO 
Any complications with catheter (dislodgement, signs of infection)
NO   YES  Please detail:  
Nurses’ satisfaction with catheter YES  NO 
Comments
30 hours postoperative
Are you experiencing pain now? YES  NO 
On this scale, please indicate the worst pain you have had in the past 24 hours
0-----------------------------------------------------------------------------------100  
No pain Worst pain possible
On this scale, please indicate the pain you experience when you are in bed
0-----------------------------------------------------------------------------------100  
No pain Worst pain possible
On this scale, please indicate the pain you experience when you get out of bed
0-----------------------------------------------------------------------------------100  
No pain Worst pain possible
Are you experiencing itchiness? YES  NO 
Have you felt nauseous or vomited in the past 6 hours? YES  NO 
Amount of IV morphine given:  
Satisfaction with catheter? YES  NO 
Any complications with catheter (dislodgement, signs of infection)
NO   YES  Please detail:  
Nurses’ satisfaction with catheter YES  NO 
Comments
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11  Appendix F:  Statistical data and tables
+-------------------+
| Key               |
|-------------------|
|     frequency     |
| column percentage |
+-------------------+
Enumerating sample-space combinations:
stage 5:  enumerations = 1
stage 4:  enumerations = 2
stage 3:  enumerations = 2
stage 2:  enumerations = 2
stage 1:  enumerations = 0
           |         group
      race |   Control     Device |     Total
-----------+----------------------+----------
   african |        15         12 |        27 
           |     68.18      66.67 |     67.50 
-----------+----------------------+----------
  coloured |         6          4 |        10 
           |     27.27      22.22 |     25.00 
-----------+----------------------+----------
    indian |         1          0 |         1 
           |      4.55       0.00 |      2.50 
-----------+----------------------+----------
     malay |         0          1 |         1 
           |      0.00       5.56 |      2.50 
-----------+----------------------+----------
     white |         0          1 |         1 
           |      0.00       5.56 |      2.50 
-----------+----------------------+----------
     Total |        22         18 |        40 
           |    100.00     100.00 |    100.00 
          Pearson chi2(4) =   3.3670   Pr = 0.498
           Fisher's exact =                 0.691
->  tab op group, col chi exact
Enumerating sample-space combinations:
stage 4:  enumerations = 1
stage 3:  enumerations = 2
stage 2:  enumerations = 2
stage 1:  enumerations = 0
           |         group
        op |   Control     Device |     Total
-----------+----------------------+----------
       TAH |        14         10 |        24 
           |     63.64      55.56 |     60.00 
-----------+----------------------+----------
 TAH & BSO |         7          7 |        14 
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           |     31.82      38.89 |     35.00 
-----------+----------------------+----------
 TAH & USO |         0          1 |         1 
           |      0.00       5.56 |      2.50 
-----------+----------------------+----------
myomectomy |         1          0 |         1 
           |      4.55       0.00 |      2.50 
-----------+----------------------+----------
     Total |        22         18 |        40 
           |    100.00     100.00 |    100.00 
          Pearson chi2(3) =   2.2896   Pr = 0.515
           Fisher's exact =                 0.721
->  tab itchiness1 group, col chi exact
           |         group
itchiness1 |   Control     Device |     Total
-----------+----------------------+----------
        no |        21         15 |        36 
           |     95.45      83.33 |     90.00 
-----------+----------------------+----------
       yes |         1          3 |         4 
           |      4.55      16.67 |     10.00 
-----------+----------------------+----------
     Total |        22         18 |        40 
           |    100.00     100.00 |    100.00 
          Pearson chi2(1) =   1.6162   Pr = 0.204
           Fisher's exact =                 0.310
   1-sided Fisher's exact =                 0.230
->  tab n_v_1 group, col chi exact
           |         group
     n_v_1 |   Control     Device |     Total
-----------+----------------------+----------
        no |        18         16 |        34 
           |     81.82      88.89 |     85.00 
-----------+----------------------+----------
       yes |         4          2 |         6 
           |     18.18      11.11 |     15.00 
-----------+----------------------+----------
     Total |        22         18 |        40 
           |    100.00     100.00 |    100.00 
          Pearson chi2(1) =   0.3882   Pr = 0.533
           Fisher's exact =                 0.673
   1-sided Fisher's exact =                 0.435
->  tab pain_now6 group, col chi exact
           |         group
 pain_now6 |   Control     Device |     Total
-----------+----------------------+----------
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        no |        13         13 |        26 
           |     59.09      72.22 |     65.00 
-----------+----------------------+----------
       yes |         9          5 |        14 
           |     40.91      27.78 |     35.00 
-----------+----------------------+----------
     Total |        22         18 |        40 
           |    100.00     100.00 |    100.00 
          Pearson chi2(1) =   0.7504   Pr = 0.386
           Fisher's exact =                 0.510
   1-sided Fisher's exact =                 0.298
->  tab itchiness6 group, col chi exact
           |         group
itchiness6 |   Control     Device |     Total
-----------+----------------------+----------
        no |        20         13 |        33 
           |     90.91      72.22 |     82.50 
-----------+----------------------+----------
       yes |         2          5 |         7 
           |      9.09      27.78 |     17.50 
-----------+----------------------+----------
     Total |        22         18 |        40 
           |    100.00     100.00 |    100.00 
          Pearson chi2(1) =   2.3945   Pr = 0.122
           Fisher's exact =                 0.211
   1-sided Fisher's exact =                 0.130
tab n_v_6 group, col chi exact
           |         group
     n_v_6 |   Control     Device |     Total
-----------+----------------------+----------
        no |        16         12 |        28 
           |     72.73      66.67 |     70.00 
-----------+----------------------+----------
       yes |         6          6 |        12 
           |     27.27      33.33 |     30.00 
-----------+----------------------+----------
     Total |        22         18 |        40 
           |    100.00     100.00 |    100.00 
          Pearson chi2(1) =   0.1732   Pr = 0.677
           Fisher's exact =                 0.738
   1-sided Fisher's exact =                 0.471
->  tab itchiness24 group, col chi exact
itchiness2 |         group
         4 |   Control     Device |     Total
-----------+----------------------+----------
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        no |        11         10 |        21 
           |     52.38      55.56 |     53.85 
-----------+----------------------+----------
       yes |        10          8 |        18 
           |     47.62      44.44 |     46.15 
-----------+----------------------+----------
     Total |        21         18 |        39 
           |    100.00     100.00 |    100.00 
          Pearson chi2(1) =   0.0393   Pr = 0.843
           Fisher's exact =                 1.000
   1-sided Fisher's exact =                 0.549
->  tab n_v_24 group, col chi exact
           |         group
    n_v_24 |   Control     Device |     Total
-----------+----------------------+----------
        no |        13         13 |        26 
           |     61.90      72.22 |     66.67 
-----------+----------------------+----------
       yes |         8          5 |        13 
           |     38.10      27.78 |     33.33 
-----------+----------------------+----------
     Total |        21         18 |        39 
           |    100.00     100.00 |    100.00 
          Pearson chi2(1) =   0.4643   Pr = 0.496
           Fisher's exact =                 0.734
   1-sided Fisher's exact =                 0.368
->  tab itchiness30 group, col chi exact
itchiness3 |         group
         0 |   Control     Device |     Total
-----------+----------------------+----------
        no |        10          8 |        18 
           |     47.62      44.44 |     46.15 
-----------+----------------------+----------
       yes |        11         10 |        21 
           |     52.38      55.56 |     53.85 
-----------+----------------------+----------
     Total |        21         18 |        39 
           |    100.00     100.00 |    100.00 
          Pearson chi2(1) =   0.0393   Pr = 0.843
           Fisher's exact =                 1.000
   1-sided Fisher's exact =                 0.549
->  tab n_v_30 group, col chi exact
           |         group
    n_v_30 |   Control     Device |     Total
100
-----------+----------------------+----------
        no |        16         17 |        33 
           |     76.19      94.44 |     84.62 
-----------+----------------------+----------
       yes |         5          1 |         6 
           |     23.81       5.56 |     15.38 
-----------+----------------------+----------
     Total |        21         18 |        39 
           |    100.00     100.00 |    100.00 
          Pearson chi2(1) =   2.4809   Pr = 0.115
           Fisher's exact =                 0.190
   1-sided Fisher's exact =                 0.129
->  ttest age, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      22    42.54545    2.083461    9.772299    38.21266    
46.87825
  Device |      18    43.61111    1.730425    7.341573    39.96023    
47.26199
---------+---------------------------------------------------------------
-----
combined |      40      43.025    1.371172    8.672052    40.25154    
45.79846
---------+---------------------------------------------------------------
-----
    diff |           -1.065657    2.708354               -6.540855    
4.409542
-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =  -
0.3935
Ho: diff = 0                             Welch's degrees of freedom =   
39.672
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.3480         Pr(|T| > |t|) = 0.6961          Pr(T > t) = 
0.6520
->  ranksum age, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
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     Control |       22       398.5         451
      Device |       18       421.5         369
-------------+---------------------------------
    combined |       40         820         820
unadjusted variance     1353.00
adjustment for ties       -7.87
                     ----------
adjusted variance       1345.13
Ho: age(group==Control) = age(group==Device)
             z =  -1.431
    Prob > |z| =   0.1523
->  ttest bmi, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      22    28.79091    1.564707    7.339126    25.53692     
32.0449
  Device |      18    31.12222    1.237343      5.2496    28.51166    
33.73279
---------+---------------------------------------------------------------
-----
combined |      40       29.84    1.029506    6.511166    27.75763    
31.92237
---------+---------------------------------------------------------------
-----
    diff |           -2.331313    1.994824               -6.365443    
1.702816
-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =  -
1.1687
Ho: diff = 0                             Welch's degrees of freedom =  
39.2384
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.1248         Pr(|T| > |t|) = 0.2496          Pr(T > t) = 
0.8752
->  ranksum bmi, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
     Control |       22       386.5         451
      Device |       18       433.5         369
102
-------------+---------------------------------
    combined |       40         820         820
unadjusted variance     1353.00
adjustment for ties       -0.25
                     ----------
adjusted variance       1352.75
Ho: bmi(group==Control) = bmi(group==Device)
             z =  -1.754
    Prob > |z| =   0.0795
->  ttest pain_last1, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      22    72.45455    5.933242    27.82937    60.11569     
84.7934
  Device |      18    46.88889    6.978557    29.60751    32.16542    
61.61236
---------+---------------------------------------------------------------
-----
combined |      40       60.95    4.911845    31.06523    51.01486    
70.88514
---------+---------------------------------------------------------------
-----
    diff |            25.56566    9.159892                 7.01253    
44.11878
-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =   
2.7910
Ho: diff = 0                             Welch's degrees of freedom =  
37.3927
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.9959         Pr(|T| > |t|) = 0.0082          Pr(T > t) = 
0.0041
->  ttest static1, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
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---------+---------------------------------------------------------------
-----
 Control |      22       59.25    7.615897    35.72173    43.41187    
75.08813
  Device |      18    34.88889    8.352875    35.43825    17.26586    
52.51191
---------+---------------------------------------------------------------
-----
combined |      40     48.2875    5.884679    37.21798    36.38461    
60.19039
---------+---------------------------------------------------------------
-----
    diff |            24.36111    11.30365                1.489048    
47.23317
-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =   
2.1552
Ho: diff = 0                             Welch's degrees of freedom =  
38.5633
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.9813         Pr(|T| > |t|) = 0.0375          Pr(T > t) = 
0.0187
->  ranksum static1, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
     Control |       22       523.5         451
      Device |       18       296.5         369
-------------+---------------------------------
    combined |       40         820         820
unadjusted variance     1353.00
adjustment for ties       -4.95
                     ----------
adjusted variance       1348.05
Ho: static1(group==Control) = static1(group==Device)
             z =   1.975
    Prob > |z| =   0.0483
->  ttest dynamic1, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
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 Control |      21    67.16667    6.216849    28.48918    54.19855    
80.13479
  Device |      18    39.41667    8.558645    36.31126     21.3595    
57.47383
---------+---------------------------------------------------------------
-----
combined |      39    54.35897    5.577994    34.83456    43.06692    
65.65103
---------+---------------------------------------------------------------
-----
    diff |               27.75    10.57826                6.246406    
49.25359
-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =   
2.6233
Ho: diff = 0                             Welch's degrees of freedom =  
33.7452
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.9935         Pr(|T| > |t|) = 0.0130          Pr(T > t) = 
0.0065
->  ranksum dynamic1, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
     Control |       21         502         420
      Device |       18         278         360
-------------+---------------------------------
    combined |       39         780         780
unadjusted variance     1260.00
adjustment for ties       -4.08
                     ----------
adjusted variance       1255.92
Ho: dynamic1(group==Control) = dynamic1(group==Device)
             z =   2.314
    Prob > |z| =   0.0207
->  ttest morph_given1, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      22    4.890909    .7677174    3.600914    3.294353    
6.487465
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  Device |      17    3.352941    .6470588    2.667892    1.981238    
4.724645
---------+---------------------------------------------------------------
-----
combined |      39    4.220513    .5252489    3.280178    3.157202    
5.283824
---------+---------------------------------------------------------------
-----
    diff |            1.537968    1.004029               -.4930289    
3.568965
-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =   
1.5318
Ho: diff = 0                             Welch's degrees of freedom =  
38.9068
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.9332         Pr(|T| > |t|) = 0.1337          Pr(T > t) = 
0.0668
->  ranksum morph_given1, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
     Control |       22         491         440
      Device |       17         289         340
-------------+---------------------------------
    combined |       39         780         780
unadjusted variance     1246.67
adjustment for ties      -21.83
                     ----------
adjusted variance       1224.84
Ho: morph~n1(group==Control) = morph~n1(group==Device)
             z =   1.457
    Prob > |z| =   0.1451
->  ttest morph_att1, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      22    7.818182    1.897408    8.899633    3.872306    
11.76406
  Device |      17    5.470588    2.255903    9.301328    .6882866    
10.25289
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---------+---------------------------------------------------------------
-----
combined |      39    6.794872    1.446378    9.032629    3.866832    
9.722912
---------+---------------------------------------------------------------
-----
    diff |            2.347594    2.947755               -3.632433     
8.32762
-------------------------------------------------------------------------
-----
   diff = mean(Control) - mean(Device)                           t =   
0.7964
Ho: diff = 0                             Welch's degrees of freedom =  
35.7071
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.7845         Pr(|T| > |t|) = 0.4311          Pr(T > t) = 
0.2155
->  ranksum morph_att1, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
     Control |       22       489.5         440
      Device |       17       290.5         340
-------------+---------------------------------
    combined |       39         780         780
unadjusted variance     1246.67
adjustment for ties      -28.39
                     ----------
adjusted variance       1218.28
Ho: morph~t1(group==Control) = morph~t1(group==Device)
             z =   1.418
    Prob > |z| =   0.1561
->  ttest pain_last6, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      22    60.43182    6.740979    31.61799    46.41319    
74.45045
  Device |      18    35.86111    7.830601    33.22243    19.33999    
52.38223
---------+---------------------------------------------------------------
-----
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combined |      40      49.375    5.414479    34.24417    38.42318    
60.32682
---------+---------------------------------------------------------------
-----
    diff |            24.57071    10.33243                3.646862    
45.49455
-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =   
2.3780
Ho: diff = 0                             Welch's degrees of freedom =  
37.6203
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.9887         Pr(|T| > |t|) = 0.0226          Pr(T > t) = 
0.0113
->  ranksum pain_last6, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
     Control |       22       536.5         451
      Device |       18       283.5         369
-------------+---------------------------------
    combined |       40         820         820
unadjusted variance     1353.00
adjustment for ties       -0.76
                     ----------
adjusted variance       1352.24
Ho: pain_l~6(group==Control) = pain_l~6(group==Device)
             z =   2.325
    Prob > |z| =   0.0201
->  ttest static6, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      22    25.79545    3.946155    18.50911    17.58898    
34.00193
  Device |      18    26.88889    6.487363    27.52355    13.20175    
40.57603
---------+---------------------------------------------------------------
-----
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combined |      40     26.2875    3.588125     22.6933    19.02983    
33.54517
---------+---------------------------------------------------------------
-----
    diff |           -1.093434    7.593288               -16.60017     
14.4133
-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =  -
0.1440
Ho: diff = 0                             Welch's degrees of freedom =  
30.0381
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.4432         Pr(|T| > |t|) = 0.8865          Pr(T > t) = 
0.5568
->  ranksum static6, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
     Control |       22       470.5         451
      Device |       18       349.5         369
-------------+---------------------------------
    combined |       40         820         820
unadjusted variance     1353.00
adjustment for ties       -1.27
                     ----------
adjusted variance       1351.73
Ho: static6(group==Control) = static6(group==Device)
             z =   0.530
    Prob > |z| =   0.5958
->  ttest dynamic6, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      22    48.72727    6.491147    30.44618    35.22819    
62.22635
  Device |      18    33.97222    7.396174    31.37931    18.36766    
49.57678
---------+---------------------------------------------------------------
-----
combined |      40     42.0875    4.958866    31.36262    32.05725    
52.11775
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---------+---------------------------------------------------------------
-----
    diff |            14.75505    9.840649               -5.167023    
34.67712
-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =   
1.4994
Ho: diff = 0                             Welch's degrees of freedom =  
37.9581
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.9290         Pr(|T| > |t|) = 0.1420          Pr(T > t) = 
0.0710
->  ranksum dynamic6, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
     Control |       22         512         451
      Device |       18         308         369
-------------+---------------------------------
    combined |       40         820         820
unadjusted variance     1353.00
adjustment for ties       -1.78
                     ----------
adjusted variance       1351.22
Ho: dynamic6(group==Control) = dynamic6(group==Device)
             z =   1.659
    Prob > |z| =   0.0970
->  ttest morph_given6, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      22    8.227273    1.343466    6.301412    5.433383    
11.02116
  Device |      18    10.83333    2.088327    8.860023    6.427348    
15.23932
---------+---------------------------------------------------------------
-----
combined |      40         9.4    1.197112      7.5712    6.978613    
11.82139
---------+---------------------------------------------------------------
-----
110
    diff |           -2.606061    2.483145               -7.668676    
2.456555
-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =  -
1.0495
Ho: diff = 0                             Welch's degrees of freedom =  
31.2732
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.1510         Pr(|T| > |t|) = 0.3020          Pr(T > t) = 
0.8490
->  ranksum morph_given6, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
     Control |       22         418         451
      Device |       18         402         369
-------------+---------------------------------
    combined |       40         820         820
unadjusted variance     1353.00
adjustment for ties       -5.97
                     ----------
adjusted variance       1347.03
Ho: morph_~6(group==Control) = morph_~6(group==Device)
             z =  -0.899
    Prob > |z| =   0.3686
->  ttest morphi_att6, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      22    16.59091    4.756704    22.31092    6.698802    
26.48302
  Device |      18    33.55556    13.48183    57.19854     5.11139    
61.99972
---------+---------------------------------------------------------------
-----
combined |      40      24.225    6.646812    42.03813    10.78055    
37.66945
---------+---------------------------------------------------------------
-----
    diff |           -16.96465    14.29636               -46.63556    
12.70627
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-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =  -
1.1866
Ho: diff = 0                             Welch's degrees of freedom =  
21.7212
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.1241         Pr(|T| > |t|) = 0.2482          Pr(T > t) = 
0.8759
->  ranksum morphi_att6, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
     Control |       22         425         451
      Device |       18         395         369
-------------+---------------------------------
    combined |       40         820         820
unadjusted variance     1353.00
adjustment for ties       -3.55
                     ----------
adjusted variance       1349.45
Ho: morphi~6(group==Control) = morphi~6(group==Device)
             z =  -0.708
    Prob > |z| =   0.4791
->  ttest pain_last24, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      21    54.30952    6.266167    28.71519    41.23853    
67.38052
  Device |      18    50.52778    7.651036     32.4606     34.3855    
66.67005
---------+---------------------------------------------------------------
-----
combined |      39     52.5641    4.827845    30.14988    42.79064    
62.33756
---------+---------------------------------------------------------------
-----
    diff |            3.781746     9.88955               -16.27143    
23.83492
-------------------------------------------------------------------------
-----
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    diff = mean(Control) - mean(Device)                           t =   
0.3824
Ho: diff = 0                             Welch's degrees of freedom =  
36.1957
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.6478         Pr(|T| > |t|) = 0.7044          Pr(T > t) = 
0.3522
->  ranksum pain_last24, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
     Control |       21       439.5         420
      Device |       18       340.5         360
-------------+---------------------------------
    combined |       39         780         780
unadjusted variance     1260.00
adjustment for ties       -0.77
                     ----------
adjusted variance       1259.23
Ho: pain_l~4(group==Control) = pain_l~4(group==Device)
             z =   0.550
    Prob > |z| =   0.5827
->  ttest static24, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      21    28.69048    6.232545    28.56111    15.68962    
41.69134
  Device |      18    22.52778    3.823618    16.22224    14.46065    
30.59491
---------+---------------------------------------------------------------
-----
combined |      39    25.84615    3.778319    23.59559    18.19735    
33.49496
---------+---------------------------------------------------------------
-----
    diff |            6.162698    7.311954               -8.700151    
21.02555
-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =   
0.8428
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Ho: diff = 0                             Welch's degrees of freedom =  
33.8041
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.7974         Pr(|T| > |t|) = 0.4053          Pr(T > t) = 
0.2026
->  ranksum static24, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
     Control |       21       423.5         420
      Device |       18       356.5         360
-------------+---------------------------------
    combined |       39         780         780
unadjusted variance     1260.00
adjustment for ties       -0.89
                     ----------
adjusted variance       1259.11
Ho: static24(group==Control) = static24(group==Device)
             z =   0.099
    Prob > |z| =   0.9214
->  ttest dynamic24, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      21    60.88095    5.879029     26.9411    48.61751    
73.14439
  Device |      18    39.16667    6.638297    28.16391    25.16108    
53.17225
---------+---------------------------------------------------------------
-----
combined |      39    50.85897     4.68804     29.2768    41.36853    
60.34941
---------+---------------------------------------------------------------
-----
    diff |            21.71429    8.867354                3.755475     
39.6731
-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =   
2.4488
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Ho: diff = 0                             Welch's degrees of freedom =  
37.5046
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.9904         Pr(|T| > |t|) = 0.0191          Pr(T > t) = 
0.0096
->  ranksum dynamic24, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
     Control |       21       501.5         420
      Device |       18       278.5         360
-------------+---------------------------------
    combined |       39         780         780
unadjusted variance     1260.00
adjustment for ties       -0.77
                     ----------
adjusted variance       1259.23
Ho: dynam~24(group==Control) = dynam~24(group==Device)
             z =   2.297
    Prob > |z| =   0.0216
->  ttest morph_given24, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      21    24.66667    2.117201    9.702233    20.25026    
29.08307
  Device |      18    25.11111    3.938986     16.7117    16.80058    
33.42165
---------+---------------------------------------------------------------
-----
combined |      39    24.87179    2.115485     13.2112    20.58922    
29.15437
---------+---------------------------------------------------------------
-----
    diff |           -.4444444    4.471929               -9.613176    
8.724288
-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =  -
0.0994
Ho: diff = 0                             Welch's degrees of freedom =  
27.4419
115
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.4608         Pr(|T| > |t|) = 0.9216          Pr(T > t) = 
0.5392
->  ranksum morph_given24, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
     Control |       21       441.5         420
      Device |       18       338.5         360
-------------+---------------------------------
    combined |       39         780         780
unadjusted variance     1260.00
adjustment for ties       -3.06
                     ----------
adjusted variance       1256.94
Ho: morp~n24(group==Control) = morp~n24(group==Device)
             z =   0.606
    Prob > |z| =   0.5442
->  ttest morph_att24, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      21    36.28571     4.75051    21.76957    26.37632     
46.1951
  Device |      18    49.66667    10.42809    44.24265    27.66532    
71.66802
---------+---------------------------------------------------------------
-----
combined |      39    42.46154    5.479054    34.21668    31.36977     
53.5533
---------+---------------------------------------------------------------
-----
    diff |           -13.38095    11.45916               -36.99556    
10.23365
-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =  -
1.1677
Ho: diff = 0                             Welch's degrees of freedom =  
24.7107
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    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.1270         Pr(|T| > |t|) = 0.2541          Pr(T > t) = 
0.8730
->  ranksum morph_att24, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
     Control |       21         405         420
      Device |       18         375         360
-------------+---------------------------------
    combined |       39         780         780
unadjusted variance     1260.00
adjustment for ties       -0.89
                     ----------
adjusted variance       1259.11
Ho: morp~t24(group==Control) = morp~t24(group==Device)
             z =  -0.423
    Prob > |z| =   0.6725
->  ttest pain_last30, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      21    45.90476    7.621134    34.92443    30.00735    
61.80217
  Device |      18    41.66667    8.400319    35.63954    23.94354    
59.38979
---------+---------------------------------------------------------------
-----
combined |      39    43.94872    5.581043     34.8536    32.65049    
55.24695
---------+---------------------------------------------------------------
-----
    diff |            4.238095    11.34227               -18.72632    
27.20251
-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =   
0.3737
Ho: diff = 0                             Welch's degrees of freedom =  
37.8396
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
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 Pr(T < t) = 0.6446         Pr(|T| > |t|) = 0.7107          Pr(T > t) = 
0.3554
->  ranksum pain_last30, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
     Control |       21         434         420
      Device |       18         346         360
-------------+---------------------------------
    combined |       39         780         780
unadjusted variance     1260.00
adjustment for ties       -1.28
                     ----------
adjusted variance       1258.72
Ho: pain_l~0(group==Control) = pain_l~0(group==Device)
             z =   0.395
    Prob > |z| =   0.6931
->  ttest static30, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      21     27.2381    5.026077    23.03238    16.75388    
37.72231
  Device |      18    20.05556    5.459131    23.16113    8.537797    
31.57331
---------+---------------------------------------------------------------
-----
combined |      39    23.92308    3.694588    23.07269    16.44377    
31.40238
---------+---------------------------------------------------------------
-----
    diff |             7.18254    7.420482               -7.839113    
22.20419
-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =   
0.9679
Ho: diff = 0                             Welch's degrees of freedom =  
38.0253
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
118
 Pr(T < t) = 0.8304         Pr(|T| > |t|) = 0.3392          Pr(T > t) = 
0.1696
->  ranksum static30, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
     Control |       21       462.5         420
      Device |       18       317.5         360
-------------+---------------------------------
    combined |       39         780         780
unadjusted variance     1260.00
adjustment for ties       -0.89
                     ----------
adjusted variance       1259.11
Ho: static30(group==Control) = static30(group==Device)
             z =   1.198
    Prob > |z| =   0.2310
->  ttest dynamic30, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      21    54.30952    6.825153    31.27678     40.0725    
68.54654
  Device |      18    32.55556    6.193488    26.27674    19.48844    
45.62267
---------+---------------------------------------------------------------
-----
combined |      39    44.26923    4.921065    30.73204    34.30705    
54.23141
---------+---------------------------------------------------------------
-----
    diff |            21.75397    9.216399                 3.11169    
40.39625
-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =   
2.3604
Ho: diff = 0                             Welch's degrees of freedom =   
38.977
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.9883         Pr(|T| > |t|) = 0.0234          Pr(T > t) = 
0.0117
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->  ranksum dynamic30, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
     Control |       21       490.5         420
      Device |       18       289.5         360
-------------+---------------------------------
    combined |       39         780         780
unadjusted variance     1260.00
adjustment for ties       -0.64
                     ----------
adjusted variance       1259.36
Ho: dynam~30(group==Control) = dynam~30(group==Device)
            z =   1.987
    Prob > |z| =   0.0470
->  ttest morph_given30, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      21    8.333333    1.033564    4.736384    6.177357    
10.48931
  Device |      18    5.777778    1.068123    4.531661    3.524236     
8.03132
---------+---------------------------------------------------------------
-----
combined |      39    7.153846     .762249    4.760244    5.610754    
8.696939
---------+---------------------------------------------------------------
-----
    diff |            2.555556    1.486318               -.4519492     
5.56306
-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =   
1.7194
Ho: diff = 0                             Welch's degrees of freedom =  
38.5416
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.9532         Pr(|T| > |t|) = 0.0936          Pr(T > t) = 
0.0468
->  ranksum morph_given30, by(group)
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Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
-------------+---------------------------------
     Control |       21         480         420
      Device |       18         300         360
-------------+---------------------------------
    combined |       39         780         780
unadjusted variance     1260.00
adjustment for ties       -7.14
                     ----------
adjusted variance       1252.86
Ho: morp~n30(group==Control) = morp~n30(group==Device)
             z =   1.695
    Prob > |z| =   0.0901
->  ttest morph_att30, by( group) unequal welch
Two-sample t test with unequal variances
-------------------------------------------------------------------------
-----
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. 
Interval]
---------+---------------------------------------------------------------
-----
 Control |      21    12.57143    2.094859    9.599851    8.201629    
16.94123
  Device |      18    14.72222    5.894389    25.00778    2.286148     
27.1583
---------+---------------------------------------------------------------
-----
combined |      39     13.5641    2.906504    18.15111    7.680193    
19.44801
---------+---------------------------------------------------------------
-----
    diff |           -2.150794    6.255579               -15.13184    
10.83025
-------------------------------------------------------------------------
-----
    diff = mean(Control) - mean(Device)                           t =  -
0.3438
Ho: diff = 0                             Welch's degrees of freedom =  
21.7753
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 
0
 Pr(T < t) = 0.3671         Pr(|T| > |t|) = 0.7343          Pr(T > t) = 
0.6329
->  ranksum morph_att30, by(group)
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
       group |      obs    rank sum    expected
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-------------+---------------------------------
     Control |       21       455.5         420
      Device |       18       324.5         360
-------------+---------------------------------
    combined |       39         780         780
unadjusted variance     1260.00
adjustment for ties       -4.21
                     ----------
adjusted variance       1255.79
Ho: morp~t30(group==Control) = morp~t30(group==Device)
             z =   1.002
    Prob > |z| =   0.3165
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12 Appendix I:  Feedback Form
Questionnaire on the Morphine PCA pumps and ON-Q pain buster catheters
Thank you for taking the time to complete this feedback form.  
Did you find that the PCA pumps benefited the patients?
In what why?
Any problems with the PCA pumps?
Were you aware if the wound catheters were used on the trial patients?
If so did you think that the catheters benefited the patients’ analgesia?
Any comments?
These comments will be reported in the discussion of the research report
Many thanks for your time, it is very much appreciated
Samantha Russell
26 August 2008
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